

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 November 2001 (01.11.2001)

PCT

(10) International Publication Number
WO 01/81411 A2

(51) International Patent Classification⁷: **C07K 14/705**

(21) International Application Number: **PCT/US01/13371**

(22) International Filing Date: **27 April 2001 (27.04.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/199,950 27 April 2000 (27.04.2000) US

(71) Applicant: **LEXICON GENETICS INCORPORATED**
[US/US]; 4000 Research Forest Drive, The Woodlands, TX
77381 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

(72) Inventors: **WANG, Xiaoming**; 4088 Commerical Avenue, Northbrook, IL 60062 (US). **WALKE, D., Wade**; 7507 Danehill Drive, Spring, TX 77389 (US). **SCOVILLE, John**; 8222 Kingsbrook Drive #543, Houston, TX 77024 (US).

(74) Agents: **GARRETT, Arthur, S.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC 20005-3315 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/81411 A2

(54) Title: **NOVEL MEMBRANE PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME**

(57) Abstract: The nucleotide and amino acid sequences of several novel G protein coupled receptors are described.

NOVEL MEMBRANE PROTEINS AND POLYNUCLEOTIDES ENCODING THE SAME

DESCRIPTION OF THE INVENTION

[001] The present application claims priority to U.S. Provisional Application Number 60/199,950, which was filed April 27, 2000. The entire contents of U.S. Provisional Application Number 60/199,950 are incorporated by reference herein for any purpose.

Field of the Invention

[002] The present invention relates to the discovery, identification and characterization of novel human polynucleotides that encode membrane associated proteins and receptors. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that lack the disclosed genes, or over express the disclosed genes, or antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed genes that can be used for diagnosis, drug screening, clinical trial monitoring, and/or the treatment of physiological or behavioral disorders.

Background of the Invention

[003] Membrane receptor proteins can serve as integral components of cellular mechanisms for sensing their environment, and maintaining cellular homeostasis and function. Accordingly, membrane receptor proteins are often involved in signal transduction pathways that control cell physiology, chemical communication, and gene expression. A particularly relevant class of membrane receptors are those typically

characterized by the presence of 7 conserved transmembrane domains that are interconnected by nonconserved hydrophilic loops. Such, "7TM receptors" include a superfamily of receptors known as G-protein coupled receptors (GPCRs). GPCRs are typically involved in signal transduction pathways involving G-proteins or PPG proteins. As such, the GPCR family includes many receptors that are known to serve as drug targets for therapeutic agents.

SUMMARY OF THE INVENTION

[004] The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel GPCRs, and the corresponding novel GPCR (NGPCR) amino acid sequences. The NGPCRs described for the first time herein, are transmembrane proteins that span the cellular membrane and are involved in signal transduction after ligand binding. The described NGPCRs have structural motifs found in the 7TM receptor family. Expression of the described NGPCRs can be detected in human placenta, bone marrow, trachea, testis, liver, and kidney cells. The novel human GPCR sequences described herein encode proteins of 769, 296, 848, 481, 423, 560, 502, 241, and 320 amino acids in length (see respectively SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, and 18). The described NGPCRs have multiple transmembrane regions (of about 20-30 amino acids) characteristic of 7TM proteins as well as several predicted cytoplasmic domains.

[005] Additionally contemplated are "knockout" ES cells that have been engineered using conventional methods (see, for example, PCT Application No. PCT/US98/03243, filed February 20, 1998, herein incorporated by reference). A gene trapped knockout ES cell line has been produced, targeting a murine homolog of the

described human sequences. Accordingly, an additional aspect of the present invention includes knockout cells and animals having genetically engineered mutations in the gene encoding the presently described NGPCRs.

[006] The invention encompasses the nucleotide sequences presented in the Sequence Listing, host cells expressing such nucleotide sequences, and the expression products of such nucleotide sequences, and: (a) nucleotide sequences that encode mammalian homologs of the described NGPCRs, including the specifically described human NGPCRs, and the human NGPCR gene products; (b) nucleotide sequences that encode one or more portions of the NGPCRs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of the described extracellular domain(s) ECD, one or more transmembrane domain(s) (TM) first disclosed herein, and the cytoplasmic domain(s) (CD); (c) isolated nucleotide sequences that encode mutants, engineered or naturally occurring, of the described NGPCRs in which all or a part of at least one of the domains is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble receptors in which all or a portion of the TM is deleted, and nonfunctional receptors in which all or a portion of the CD is deleted; and (d) nucleotides that encode fusion proteins containing the coding region from an NGPCR, or one of its domains (*e.g.*, an ECD) fused to another peptide or polypeptide.

[007] The invention also encompasses agonists and antagonists of the NGPCRs, including small molecules, large molecules, mutant NGPCR proteins, or portions thereof that compete with the native NGPCR, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described

NGPCR (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NGPCR gene (e.g., expression constructs that place the described gene under the control of a strong promoter system), and transgenic animals that express a NGPCR transgene or "knock-outs" that do not express a functional NGPCR.

[008] Further, the present invention also relates to methods for the use of the described NGPCR gene and/or NGPCR gene products for the identification of compounds that modulate, *i.e.*, act as agonists or antagonists, of NGPCR gene expression and or NGPCR gene product activity. Such compounds can be used as therapeutic agents for the treatment of various symptomatic representations of biological disorders or imbalances.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

[009] The Sequence Listing provides the sequences of the certain NGPCR ORFs, the amino acid sequences encoded thereby, as well as an ORF with surrounding 5' and 3' regions (SEQ ID NO:19).

DESCRIPTION OF EMBODIMENTS

[010] The human NGPCRs, described for the first time herein, are novel receptor proteins that are expressed in human cells. The human NGPCR sequences were obtained using sequences from gene trapped human cells and cDNA clones isolated from human trachea, liver, and testis cDNA libraries (Edge Biosystems, Gaithersburg, MD, and Clontech, Palo Alto, CA). The described NGPCRs are transmembrane proteins that fall within the 7TM family of receptors. As with other GPCRs, signal transduction is triggered when a ligand binds to the receptor. Interfering

with the binding of the natural ligand, or neutralizing or removing the ligand, or interfering with its binding to a NGPCR will affect NGPCR mediated signal transduction. Because of their biological significance, 7TM, and particularly GPCR, proteins have been subjected to intense scientific/commercial scrutiny (see, for example, U.S. Application Ser. Nos. 08/820,521, filed March 19, 1997, and 08/833,226, filed April 17, 1997 both of which are herein incorporated by reference in their entirety for applications, uses, and assays involving the described NGPCRs). In addition to 7TM proteins, the presently described NGPCRs share significant homology with a domain of the mammalian TRK-fused gene, latrophilin (latrotoxin receptor), and peptide hormone receptors.

[011] The invention encompasses the use of the described NGPCR nucleotides, NGPCR proteins and peptides, as well as antibodies, preferably humanized monoclonal antibodies, or binding fragments, domains, or fusion proteins thereof, to the NGPCRs (which can, for example, act as NGPCR agonists or antagonists), antagonists that inhibit receptor activity or expression, or agonists that activate receptor activity or increase its expression in the diagnosis and treatment of disease.

[012] In particular, the invention described in the subsections below encompasses NGPCR polypeptides or peptides corresponding to functional domains of NGPCR (e.g., ECD, TM or CD), mutated, truncated or deleted NGPCRs (e.g., NGPCRs missing one or more functional domains or portions thereof, such as, Δ ECD, Δ TM and/or Δ CD), NGPCR fusion proteins (e.g., a NGPCR or a functional domain of a NGPCR, such as the ECD, fused to an unrelated protein or peptide such as an

immunoglobulin constant region, *i.e.*, IgFc), nucleotide sequences encoding such products, and host cell expression systems that can produce such NGPCR products.

[013] The invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NGPCR, as well as compounds or nucleotide constructs that inhibit expression of a NGPCR gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote expression of NGPCR (*e.g.*, expression constructs in which NGPCR coding sequences are operatively associated with expression control elements such as promoters, promoter/enhancers, *etc.*). The invention also relates to host cells and animals genetically engineered to express the human NGPCRs (or mutants thereof) or to inhibit or "knock-out" expression of the animal's endogenous NGPCR genes.

[014] The NGPCR proteins or peptides, NGPCR fusion proteins, NGPCR nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NGPCRs or inappropriately expressed NGPCRs for the diagnosis of disease. The NGPCR proteins or peptides, NGPCR fusion proteins, NGPCR nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NGPCR in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to an ECD

of a NGPCR, but can also identify compounds that affect the signal transduced by an activated NGPCR.

[015] According to certain embodiments, the nucleotide sequences encompassed by the invention can be useful for chromosome mapping. For example, the nucleotide sequences as set forth in SEQ ID NOs 1, 3, 5, 7, 9, 11, 13, 15, 17, and 19 are found on chromosome 3 at 3q11.1 in the human genome. In certain embodiments, these sequences can act as highly specific probes to show which regions of the chromosome actually code for protein. Thus, in certain embodiments, these sequences can provide mapping information for protein coding regions within the 3q11.1 location of chromosome 3. In certain embodiments, these sequences allow for the identification of exons and the verification of splice junction sites. In certain embodiments, these sequences also can allow for the identification of the genomic locations for the NGPCR gene in mouse. This information is useful for creating "knock-out" mice in which the expression of this protein is abrogated.

[016] Finally, the NGPCR protein products (especially soluble derivatives such as peptides corresponding to the NGPCR ECD, or truncated polypeptides lacking one or more TM domains) and fusion protein products (especially NGPCR-Ig fusion proteins, *i.e.*, fusions of a NGPCR, or a domain of a NGPCR, *e.g.*, ECD, Δ TM to an IgFc), antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate signal transduction which may act on downstream targets in a NGPCR-mediated signal transduction pathway) can be used for therapy of such diseases. For example, the administration of an effective amount of soluble NGPCR ECD, Δ TM, or an ECD-IgFc fusion protein or an anti-idiotypic antibody

(or its Fab) that mimics the NGPCR ECD would "mop up" or "neutralize" the endogenous NGPCR ligand, and prevent or reduce binding and receptor activation. Nucleotide constructs encoding such NGPCR products can be used to genetically engineer host cells to express such products *in vivo*; these genetically engineered cells function as "bioreactors" in the body delivering a continuous supply of a NGPCR, a NGPCR peptide, soluble ECD or Δ TM or a NGPCR fusion protein that will "mop up" or neutralize a NGPCR ligand. Nucleotide constructs encoding functional NGPCRs, mutant NGPCRs, as well as antisense and ribozyme molecules can be used in "gene therapy" approaches for the modulation of NGPCR expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

[017] Various aspects of the invention are described in greater detail in the subsections below.

THE NGPCR POLYNUCLEOTIDES

[018] The cDNA sequences and deduced amino acid sequences of certain described human NGPCRs are presented in the Sequence Listing. Several polymorphisms were identified during the sequencing of the described NGPCRs including: a C or T transition at the positions represented by, for example, nucleotide 1075 of SEQ ID NO:1 and nucleotide 211 of SEQ ID NO:9 both of which can results in a glutamine (preferred) or a stop codon being present at the corresponding amino acid positions (for example, 359 or 71 respectively)of the encoded proteins.

[019] The NGPCRs of the present invention include: (a) the human DNA sequences presented in the Sequence Listing and any additionally contemplated

nucleotide sequence encoding a contiguous and functional NGPCR open reading frame (ORF) that hybridizes to a complement of the DNA sequences presented in the Sequence Listing under highly stringent conditions, *e.g.*, hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. *et al.*, eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3) and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of the DNA sequences that encode and express an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, *e.g.*, washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989, *supra*), yet which still encode a functionally equivalent NGPCR gene product. Functional equivalents of NGPCR include naturally occurring NGPCRs present in other species, and mutant NGPCRs whether naturally occurring or engineered. The invention also includes degenerate variants of the disclosed sequences.

[020] Additionally contemplated are polynucleotides encoding NGPCR ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the polynucleotide sequences described in the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using default parameters).

[021] In certain embodiments, the invention includes nucleic acid molecules that comprise at least 300 contiguous bases of a human NGPCR nucleotide sequence.

In certain embodiments, the invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NGPCR nucleotide sequences. Such hybridization conditions may be highly stringent or moderately stringent (less highly stringent), as described above. In instances wherein the nucleic acid molecules are deoxyoligonucleotides ("DNA oligos"), such molecules (in certain embodiments, those about 16 to about 100 base long, about 20 to about 80, or about 34 to about 45 base long, or those of at least 300 nucleotides in length, or any variation or combination of sizes represented therein incorporating a contiguous region of sequence first disclosed in the present Sequence Listing) can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

[022] Alternatively, the oligonucleotides can be used singly or in chip format as hybridization probes. For example, a series of the described NGPCR oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NGPCRs. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length may partially overlap each other and/or the NGPCR sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described NGPCR polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 18 nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences may begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5'-to-3') orientation vis-a-vis the described sequence or in an antisense orientation. For

oligonucleotides probes, highly stringent conditions may refer, *e.g.*, to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos).

[023] The described oligonucleotides may encode or act as NGPCR antisense molecules, useful, for example, in NGPCR gene regulation (for and/or as antisense primers in amplification reactions of NGPCR gene nucleic acid sequences). With respect to NGPCR gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences, also useful for NGPCR gene regulation.

[024] Additionally, the antisense oligonucleotides may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[025] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

[026] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[027] In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier *et al.*, 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue *et al.*, 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue *et al.*, 1987, FEBS Lett. 215:327-330).

[028] Oligonucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein *et al.* (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin *et al.*, 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[029] Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

[030] Alternatively, suitably labeled NGPCR nucleotide probes may be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms, determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (*e.g.*, splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

[031] Further, a NGPCR gene homolog may be isolated from nucleic acid of the organism of interest by performing PCR using two degenerate oligonucleotide primer pools designed on the basis of amino acid sequences within the NGPCR gene product disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from, for example, human or non-human cell lines or tissue known or suspected to express a NGPCR gene allele.

[032] The PCR product may be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NGPCR gene. The PCR fragment may then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment may be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment may be used to isolate genomic clones via the screening of a genomic library.

[033] PCR technology may also be utilized to isolate full length cDNA sequences. For example, RNA may be isolated, following standard procedures, from an appropriate cellular or tissue source (*i.e.*, one known, or suspected, to express a NGPCR gene). A reverse transcription (RT) reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment may easily be isolated. For a review of cloning strategies which may be used, see *e.g.*, Sambrook *et al.*, 1989, *supra*.

[034] A cDNA of a mutant NGPCR gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NGPCR allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5' end of the normal gene. Using

these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NGPCR allele to that of the normal NGPCR allele, the mutation(s) responsible for the loss or alteration of function of the mutant NGPCR gene product can be ascertained.

[035] Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry the mutant NGPCR allele, or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express the mutant NGPCR allele. A normal NGPCR gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NGPCR allele in such libraries. Clones containing the mutant NGPCR gene sequences can then be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

[036] Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NGPCR allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue may be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal NGPCR gene product, as described, below, in Section 5.3. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Press, Cold Spring Harbor)

[037] Additionally, screening can be accomplished by screening with labeled NGPCR fusion proteins, such as, for example, AP-NGPCR or NGPCR-AP fusion proteins. In cases where a NGPCR mutation results in an expressed gene product with altered function (e.g., as a result of a missense or a frameshift mutation), a polyclonal set of antibodies to NGPCR are likely to cross-react with the mutant NGPCR gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known to those of skill in the art.

[038] The invention also encompasses nucleotide sequences that encode mutant NGPCRs, peptide fragments of the NGPCRs, truncated NGPCRs, and NGPCR fusion proteins. These include, but are not limited to, nucleotide sequences encoding mutant NGPCRs described below; polypeptides or peptides corresponding to one or more ECD, TM and/or CD domains of the NGPCR or portions of these domains; truncated NGPCRs in which one or two of the domains is deleted, e.g., a soluble NGPCR lacking the TM or both the TM and CD regions, or a truncated, nonfunctional NGPCR lacking all or a portion of the CD region. Nucleotides encoding fusion proteins may include, but are not limited to, full length NGPCR sequences, truncated NGPCRs, or nucleotides encoding peptide fragments of NGPCR fused to an unrelated protein or peptide, such as for example, a transmembrane sequence, which anchors the NGPCR ECD to the cell membrane; an IgFc domain which increases the stability and half life of the resulting fusion protein (e.g., NGPCR-Ig) in the bloodstream; or an enzyme, fluorescent protein, luminescent protein which can be used as a marker.

[039] The invention also encompasses (a) DNA vectors that contain any of the foregoing NGPCR coding sequences and/or their complements (*i.e.*, antisense); (b) DNA expression vectors that contain any of the foregoing NGPCR coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences; and (c) genetically engineered host cells that contain any of the foregoing NGPCR coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell. As used herein, regulatory elements include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, regulatable, viral (particularly retroviral LTR promoters) the early or late promoters of SV40 adenovirus, the lac system, the trp system, the tet system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α -mating factors.

NGPCR PROTEINS AND POLYPEPTIDES

[040] NGPCR proteins, polypeptides and peptide fragments, mutated, truncated or deleted forms of the NGPCR and/or NGPCR fusion proteins can be prepared for a variety of uses, including but not limited to the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products related to a NGPCR, as reagents in assays for screening for compounds that can be used as pharmaceutical reagents useful in the therapeutic treatment of mental,

biological, or medical disorders (*i.e.*, heartbeat rate, improper blood pressure, etc.) and disease.

[041] The Sequence Listing discloses the amino acid sequences encoded by certain NGPCR genes. The NGPCRs have initiator methionines in DNA sequence contexts consistent with translation initiation sites, followed by hydrophobic signal sequences typical of membrane associated proteins. The sequence data presented herein indicate that alternatively spliced forms of the NGPCRs exist (which may or may not be tissue specific).

[042] The NGPCR amino acid sequences of the invention include the nucleotide and amino acid sequences presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NGPCR homologues from other species are encompassed by the invention. In fact, any NGPCR protein encoded by the NGPCR nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid "triplet" codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of "Molecular Cell Biology", 1986, J. Darnell *et al.* eds., Scientific American Books, New York, NY, herein incorporated by reference) are generically representative of all the

various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

[043] The invention also encompasses proteins that are functionally equivalent to the NGPCR encoded by the described nucleotide sequences as judged by any of a number of criteria, including but not limited to the ability to bind a ligand for a NGPCR, the ability to affect an identical or complementary signal transduction pathway, a change in cellular metabolism (*e.g.*, ion flux, tyrosine phosphorylation, etc.) or a change in phenotype when the NGPCR equivalent is present in an appropriate cell type (such as the amelioration, prevention or delay of a biochemical, biophysical, or overt phenotype. Such functionally equivalent NGPCR proteins include but are not limited to additions or substitutions of amino acid residues within the amino acid sequence encoded by the NGPCR nucleotide sequences described above but which result in a silent change, thus producing a functionally equivalent gene product. For example, in certain embodiments, one can employ a conservative amino acid substitution or substitutions which may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

[044] While random mutations can be made to NGPCR DNA (using random mutagenesis techniques well known to those skilled in the art) and the resulting mutant

NGPCRs tested for activity, site-directed mutations of the NGPCR coding sequence can be engineered (using site-directed mutagenesis techniques well known to those skilled in the art) to generate mutant NGPCRs with increased function, e.g., higher binding affinity for the target ligand, and/or greater signaling capacity; or decreased function, and/or decreased signal transduction capacity. One starting point for such analysis is by aligning the disclosed human sequences with corresponding gene/protein sequences from, for example, other mammals in order to identify amino acid sequence motifs that are conserved between different species. Non-conservative changes can be engineered at variable positions to alter function, signal transduction capability, or both. Alternatively, where alteration of function is desired, deletion or non-conservative alterations of the conserved regions (*i.e.*, identical amino acids) can be engineered. For example, deletion or non-conservative alterations (substitutions or insertions) of the various conserved transmembrane domains.

[045] An additional application of the described NGPCR polynucleotide sequences is their use in the molecular mutagenesis/evolution of proteins that are at least partially encoded by the described novel sequences using, for example, polynucleotide shuffling or related methodologies. Such approaches are described in U.S. Patents Nos. 5,830,721 and 5,837,458 which are herein incorporated by reference in their entirety.

[046] Additionally contemplated uses for the described sequences include the engineering of constitutively "on" variants for use in cell assays and genetically engineered animals using the methods and applications described in U.S. Patent

Applications Ser Nos. 60/110,906, 60/106,300, 60/094,879, and 60/121,851 all of which are herein incorporated by reference in their entirety.

[047] Other mutations to the NGPCR coding sequence can be made to generate NGPCRs that are better suited for expression, scale up, etc. in the host cells chosen. For example, cysteine residues can be deleted or substituted with another amino acid in order to eliminate disulfide bridges; N-linked glycosylation sites can be altered or eliminated to achieve, for example, expression of a homogeneous product that is more easily recovered and purified from yeast hosts which are known to hyperglycosylate N-linked sites. To this end, a variety of amino acid substitutions at one or both of the first or third amino acid positions of any one or more of the glycosylation recognition sequences which occur in the ECD (N-X-S or N-X-T), and/or an amino acid deletion at the second position of any one or more such recognition sequences in the ECD will prevent glycosylation of the NGPCR at the modified tripeptide sequence. (See, e.g., Miyajima et al., 1986, EMBO J. 5(6):1193-1197).

[048] Peptides corresponding to one or more domains of the NGPCR (e.g., ECD, TM, CD, etc.), truncated or deleted NGPCRs (e.g., NGPCR in which a ECD, TM and/or CD is deleted) as well as fusion proteins in which a full length NGPCR, a NGPCR peptide, or truncated NGPCR is fused to an unrelated protein, are also within the scope of the invention and can be designed on the basis of the presently disclosed NGPCR nucleotide and NGPCR amino acid sequences. Such fusion proteins include but are not limited to IgFc fusions which stabilize the NGPCR protein or peptide and prolong half-life in vivo; or fusions to any amino acid sequence that allows the fusion protein to be anchored to the cell membrane, allowing an ECD to be exhibited on the

cell surface; or fusions to an enzyme, fluorescent protein, or luminescent protein which provide a marker function.

[049] While the NGPCR polypeptides and peptides can be chemically synthesized (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y.), large polypeptides derived from a NGPCR and full length NGPCRs can be advantageously produced by recombinant DNA technology using techniques well known in the art for expressing nucleic acid containing NGPCR gene sequences and/or coding sequences. Such methods can be used to construct expression vectors containing a presently described NGPCR nucleotide sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. See, for example, the techniques described in Sambrook et al., 1989, *supra*, and Ausubel et al., 1989, *supra*. Alternatively, RNA corresponding to all or a portion of a transcript encoded by a NGPCR nucleotide sequence may be chemically synthesized using, for example, synthesizers. See, for example, the techniques described in "Oligonucleotide Synthesis", 1984, Gait, M.J. ed., IRL Press, Oxford, which is incorporated by reference herein in its entirety.

[050] A variety of host-expression vector systems may be utilized to express the NGPCR nucleotide sequences of the invention. Where the NGPCR peptide or polypeptide is a soluble derivative (e.g., NGPCR peptides corresponding to an ECD; truncated or deleted NGPCR in which a TM and/or CD are deleted) the peptide or polypeptide can be recovered from the culture, i.e., from the host cell in cases where the NGPCR peptide or polypeptide is not secreted, and from the culture media in cases

where the NGPCR peptide or polypeptide is secreted by the cells. However, such expression systems also encompass engineered host cells that express a NGPCR, or functional equivalent, in situ, i.e., anchored in the cell membrane. Purification or enrichment of NGPCR from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the NGPCR, but to assess biological activity, e.g., in drug screening assays.

[051] The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NGPCR nucleotide sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing NGPCR nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NGPCR sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NGPCR nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

[052] In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NGPCR gene product being expressed. For example, when a large quantity of such a protein is to be produced, for the generation of pharmaceutical compositions of NGPCR protein or for raising antibodies to a NGPCR protein, for example, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NGPCR coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

[053] In an insect system, Autographa californica nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. A NGPCR gene coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NGPCR gene coding sequence will result in inactivation of the polyhedrin

gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *Spodoptera frugiperda* cells in which the inserted gene is expressed (e.g., see Smith et al., 1983, J. Virol. 46: 584; Smith, U.S. Patent No. 4,215,051). In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NGPCR nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NGPCR gene product in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NGPCR nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NGPCR gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NGPCR coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, typically are provided. Furthermore, the initiation codon typically must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by

the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bittner et al., 1987, Methods in Enzymol. 153:516-544).

[054] In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and WI38 cell lines.

[055] For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the NGPCR sequences described above may be engineered. Rather than using expression vectors that contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection

and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NGPCR gene product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NGPCR gene product.

[056] A number of selection systems can be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk-, hgprt- or aprt- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygromycin (Santerre, et al., 1984, Gene 30:147).

[057] Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88: 8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused

to an amino-terminal tag having six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺-nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

[058] NGPCR gene products can also be expressed in transgenic animals. Animals of any species, including, but not limited to, worms, mice, rats, rabbits, guinea pigs, rodents, pigs, micro-pigs, birds, goats, farm animals, and non-human primates, e.g., baboons, monkeys, and chimpanzees may be used to generate NGPCR transgenic animals.

[059] Any technique known in the art may be used to introduce a NGPCR transgene into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to pronuclear microinjection (Hoppe, P.C. and Wagner, T.E., 1989, U.S. Pat. No. 4,873,191); retrovirus mediated gene transfer into germ lines (Van der Putten et al., 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson et al., 1989, Cell 56:313-321); electroporation of embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814); and sperm-mediated gene transfer (Lavitrano et al., 1989, Cell 57:717-723); etc. For a review of such techniques, see Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229, which is incorporated by reference herein in its entirety.

[060] The present invention provides for transgenic animals that carry the NGPCR transgene in all their cells, as well as animals which carry the transgene in some, but not all their cells, i.e., mosaic animals or somatic cell transgenic animals. The transgene may be integrated as a single transgene or in concatamers, e.g., head-to-head tandems or head-to-tail tandems. The transgene may also be selectively

introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al., 1992, Proc. Natl. Acad. Sci. USA 89:6232-6236. The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

[061] When it is desired that a NGPCR transgene be integrated into the chromosomal site of the endogenous NGPCR gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous NGPCR gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous NGPCR gene (i.e., "knockout" animals).

[062] The transgene can also be selectively introduced into a particular cell type, thus inactivating the endogenous NGPCR gene in only that cell type, by following, for example, the teaching of Gu et al., 1994, Science, 265:103-106. The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

[063] Once transgenic animals have been generated, the expression of the recombinant NGPCR gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained from the animal, in situ hybridization analysis,

and RT-PCR. Samples of NGPCR gene-expressing tissue, may also be evaluated immunocytochemically using antibodies specific for the NGPCR transgene product.

ANTIBODIES TO NGPCR PROTEINS

[064] Antibodies that specifically recognize one or more epitopes of a NGPCR, or epitopes of conserved variants of a NGPCR, or peptide fragments of a NGPCR are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

[065] The antibodies of the invention may be used, for example, in the detection of NGPCR in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of NGPCR. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes, as described below, for the evaluation of the effect of test compounds on expression and/or activity of a NGPCR gene product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NGPCR-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal NGPCR activity. Thus, such antibodies may, therefore, be utilized as part of weight disorder treatment methods.

[066] For the production of antibodies, various host animals may be immunized by injection with the NGPCR, an NGPCR peptide (e.g., one corresponding

to a functional domain of the receptor, such as an ECD, TM or CD), truncated NGPCR polypeptides (NGPCR in which one or more domains, e.g., a TM or CD, has been deleted), functional equivalents of the NGPCR or mutants of the NGPCR. Such host animals may include but are not limited to rabbits, mice, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

[067] Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, *Nature* 256:495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, *Immunology Today* 4:72; Cole et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, *Monoclonal Antibodies And Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo.

Production of high titers of mAbs in vivo makes this the presently preferred method of production.

[068] In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region.

[069] Alternatively, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 334:544-546) can be adapted to produce single chain antibodies against NGPCR gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

[070] Antibody fragments that recognize specific epitopes may be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed (Huse et al., 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

[071] Antibodies to a NGPCR can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" a given NGPCR, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NGPCR ECD and competitively inhibit the binding of a ligand of NGPCR can be used to generate anti-idiotypes that "mimic" a NGPCR ECD and, therefore, bind and neutralize a ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving the NGPCR signaling pathway.

DIAGNOSIS OF ABNORMALITIES RELATED TO A NGPCR

[072] A variety of methods can be employed for the diagnostic and prognostic evaluation of disorders related to NGPCR function, and for the identification of subjects having a predisposition to such disorders.

[073] Such methods can, for example, utilize reagents such as the NGPCR nucleotide sequences described in Section 5.1, and NGPCR antibodies, as described, in Section 5.3. Specifically, such reagents may be used, for example, for: (1) the detection of the presence of NGPCR gene mutations, or the detection of either over- or under-expression of NGPCR mRNA relative to a given phenotype; (2) the detection of either an over- or an under-abundance of NGPCR gene product relative to a given phenotype; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by NGPCR.

[074] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one specific NGPCR nucleotide sequence or NGPCR antibody reagent described herein, which may be

conveniently used, e.g., in clinical settings, to diagnose patients exhibiting body weight disorder abnormalities.

[075] For the detection of NGPCR mutations, any nucleated cell can be used as a starting source for genomic nucleic acid. For the detection of NGPCR gene expression or NGPCR gene products, any cell type or tissue in which the NGPCR gene is expressed, such as, for example, stomach or brain cells can be utilized.

[076] Nucleic acid-based detection techniques and peptide detection techniques are described below.

DETECTION OF NGPCR GENES AND TRANSCRIPTS

[077] Mutations within a NGPCR gene can be detected by utilizing a number of techniques. Nucleic acid from any nucleated cell can be used as the starting point for such assay techniques, and may be isolated according to standard nucleic acid preparation procedures which are well known to those of skill in the art.

[078] DNA may be used in hybridization or amplification assays of biological samples to detect abnormalities involving NGPCR gene structure, including point mutations, insertions, deletions and chromosomal rearrangements. Such assays may include, but are not limited to, Southern analyses, single stranded conformational polymorphism analyses (SSCP), and PCR analyses.

[079] Such diagnostic methods for the detection of NGPCR gene-specific mutations can involve for example, contacting and incubating nucleic acids including recombinant DNA molecules, cloned genes or degenerate variants thereof, obtained from a sample, e.g., derived from a patient sample or other appropriate cellular source, with one or more labeled nucleic acid reagents including recombinant DNA molecules, cloned genes or degenerate variants thereof, as described in Section 5.1, under

conditions favorable for the specific annealing of these reagents to their complementary sequences within a given NGPCR gene. Preferably, the lengths of these nucleic acid reagents are at least 15 to 30 nucleotides. After incubation, all non-annealed nucleic acids are removed from the nucleic acid:NGPCR molecule hybrid. The presence of nucleic acids which have hybridized, if any such molecules exist, is then detected.

Using such a detection scheme, the nucleic acid from the cell type or tissue of interest can be immobilized, for example, to a solid support such as a membrane, or a plastic surface such as that on a microtiter plate or polystyrene beads. In this case, after incubation, non-annealed, labeled nucleic acid reagents of the type described in Section 5.1 are easily removed. Detection of the remaining, annealed, labeled NGPCR nucleic acid reagents is accomplished using standard techniques well-known to those in the art. The NGPCR gene sequences to which the nucleic acid reagents have annealed can be compared to the annealing pattern expected from a normal NGPCR gene sequence in order to determine whether a NGPCR gene mutation is present.

[080] Alternative diagnostic methods for the detection of NGPCR gene specific nucleic acid molecules, in patient samples or other appropriate cell sources, may involve their amplification, e.g., by PCR (the experimental embodiment set forth in Mullis, K.B., 1987, U.S. Patent No. 4,683,202), followed by the detection of the amplified molecules using techniques well known to those of skill in the art. The resulting amplified sequences can be compared to those which would be expected if the nucleic acid being amplified contained only normal copies of a NGPCR gene in order to determine whether a NGPCR gene mutation exists.

[081] Additionally, well-known genotyping techniques can be performed to identify individuals carrying NGPCR gene mutations. Such techniques include, for example, the use of restriction fragment length polymorphisms (RFLPs), which involve sequence variations in one of the recognition sites for the specific restriction enzyme used.

[082] Additionally, improved methods for analyzing DNA polymorphisms which can be utilized for the identification of NGPCR gene mutations have been described which capitalize on the presence of variable numbers of short, tandemly repeated DNA sequences between the restriction enzyme sites. For example, Weber (U.S. Pat. No. 5,075,217, which is incorporated herein by reference in its entirety) describes a DNA marker based on length polymorphisms in blocks of (dC-dA)_n-(dG-dT)_n short tandem repeats. The average separation of (dC-dA)_n-(dG-dT)_n blocks is estimated to be 30,000-60,000 bp. Markers which are so closely spaced exhibit a high frequency co-inheritance, and are extremely useful in the identification of genetic mutations, such as, for example, mutations within a given NGPCR gene, and the diagnosis of diseases and disorders related to NGPCR mutations.

[083] Also, Caskey et al. (U.S. Pat. No. 5,364,759, which is incorporated herein by reference in its entirety) describe a DNA profiling assay for detecting short tri and tetra nucleotide repeat sequences. The process includes extracting the DNA of interest, such as the NGPCR gene, amplifying the extracted DNA, and labeling the repeat sequences to form a genotypic map of the individual's DNA.

[084] The level of NGPCR gene expression can also be assayed by detecting and measuring NGPCR transcription. For example, RNA from a cell type or tissue

known, or suspected to express the NGPCR gene, such as brain, may be isolated and tested utilizing hybridization or PCR techniques such as are described, above. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells to be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of the NGPCR gene. Such analyses may reveal both quantitative and qualitative aspects of the expression pattern of the NGPCR gene, including activation or inactivation of NGPCR gene expression.

[085] In certain embodiments of such a detection scheme, cDNAs are synthesized from the RNAs of interest (e.g., by reverse transcription of the RNA molecule into cDNA). A sequence within the cDNA is then used as the template for a nucleic acid amplification reaction, such as a PCR amplification reaction, or the like. The nucleic acid reagents used as synthesis initiation reagents (e.g., primers) in the reverse transcription and nucleic acid amplification steps of this method can be chosen from among the NGPCR nucleic acid reagents described in Section 5.1. The preferred lengths of such nucleic acid reagents are at least 9-30 nucleotides. For detection of the amplified product, the nucleic acid amplification may be performed using radioactively or non-radioactively labeled nucleotides. Alternatively, enough amplified product may be made such that the product may be visualized by standard ethidium bromide staining, by utilizing any other suitable nucleic acid staining method, or by sequencing.

[086] Additionally, it is possible to perform such NGPCR gene expression assays "in situ", i.e., directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary.

Nucleic acid reagents such as those described above may be used as probes and/or primers for such in situ procedures (See, for example, Nuovo, G.J., 1992, "PCR In Situ Hybridization: Protocols And Applications", Raven Press, NY).

[087] Alternatively, if a sufficient quantity of the appropriate cells can be obtained, standard Northern analysis can be performed to determine the level of NGPCR mRNA expression.

DETECTION OF NGPCR GENE PRODUCTS

[088] Antibodies directed against wild type or mutant NGPCR gene products or conserved variants or peptide fragments thereof, which are discussed above, may also be used as diagnostics and prognostics, as described herein. Such diagnostic methods, may be used to detect abnormalities in the level of NGPCR gene expression, or abnormalities in the structure and/or temporal, tissue, cellular, or subcellular location of the NGPCR, and may be performed *in vivo* or *in vitro*, such as, for example, on biopsy tissue.

[089] For example, antibodies directed to epitopes of the NGPCR ECD can be used *in vivo* to detect the pattern and level of expression of the NGPCR in the body. Such antibodies can be labeled, e.g., with a radio-opaque or other appropriate compound and injected into a subject in order to visualize binding to the NGPCR expressed in the body using methods such as X-rays, CAT-scans, or MRI. Labeled antibody fragments, e.g., the Fab or single chain antibody comprising the smallest portion of the antigen binding region, are preferred for this purpose to promote crossing the blood-brain barrier and permit labeling NGPCRs expressed in the brain.

[090] Additionally, any NGPCR fusion protein or NGPCR conjugated protein whose presence can be detected, can be administered. For example, NGPCR fusion or

conjugated proteins labeled with a radio-opaque or other appropriate compound can be administered and visualized in vivo, as discussed, above for labeled antibodies. Further such NGPCR fusion proteins as AP-NGPCR or NGPCR-Ap fusion proteins can be utilized for in vitro diagnostic procedures.

[091] Alternatively, immunoassays or fusion protein detection assays, as described above, can be utilized on biopsy and autopsy samples in vitro to permit assessment of the expression pattern of the NGPCR. Such assays are not confined to the use of antibodies that define a NGPCR ECD, but can include the use of antibodies directed to epitopes of any of the domains of a NGPCR, e.g., the ECD, the TM and/or CD. The use of each or all of these labeled antibodies will yield useful information regarding translation and intracellular transport of the NGPCR to the cell surface, and can identify defects in processing.

[092] The tissue or cell type to be analyzed will generally include those which are known, or suspected, to express the NGPCR gene. The protein isolation methods employed herein may, for example, be such as those described in Harlow and Lane (Harlow, E. and Lane, D., 1988, "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York), which is incorporated herein by reference in its entirety. The isolated cells can be derived from cell culture or from a patient. The analysis of cells taken from culture may be a necessary step in the assessment of cells that could be used as part of a cell-based gene therapy technique or, alternatively, to test the effect of compounds on the expression of a NGPCR gene.

[093] For example, antibodies, or fragments of antibodies, such as those described, above, in Section 5.3, useful in the present invention may be used to

quantitatively or qualitatively detect the presence of NGPCR gene products or conserved variants or peptide fragments thereof. This can be accomplished, for example, by immunofluorescence techniques employing a fluorescently labeled antibody (see below, this Section) coupled with light microscopic, flow cytometric, or fluorimetric detection. Such techniques are especially preferred if such NGPCR gene products are expressed on the cell surface.

[094] The antibodies (or fragments thereof) or NGPCR fusion or conjugated proteins useful in the present invention may, additionally, be employed histologically, as in immunofluorescence, immunoelectron microscopy or non-immuno assays, for in situ detection of NGPCR gene products or conserved variants or peptide fragments thereof, or for NGPCR binding (in the case of labeled NGPCR ligand fusion protein).

[095] In situ detection may be accomplished by removing a histological specimen from a patient, and applying thereto a labeled antibody or fusion protein of the present invention. The antibody (or fragment) or fusion protein is preferably applied by overlaying the labeled antibody (or fragment) onto a biological sample. Through the use of such a procedure, it is possible to determine not only the presence of a NGPCR gene product, or conserved variants or peptide fragments, or NGPCR binding, but also its distribution in the examined tissue. Using the present invention, those of ordinary skill will readily perceive that any of a wide variety of histological methods (such as staining procedures) can be modified in order to achieve such in situ detection.

[096] Immunoassays and non-immunoassays for NGPCR gene products or conserved variants or peptide fragments thereof will typically comprise incubating a sample, such as a biological fluid, a tissue extract, freshly harvested cells, or lysates of

cells which have been incubated in cell culture, in the presence of a detectably labeled antibody capable of identifying NGPCR gene products or conserved variants or peptide fragments thereof, and detecting the bound antibody by any of a number of techniques well-known in the art.

[097] The biological sample may be brought in contact with and immobilized onto a solid phase support or carrier such as nitrocellulose, or other solid support which is capable of immobilizing cells, cell particles or soluble proteins. The support may then be washed with suitable buffers followed by treatment with the detectably labeled NGPCR antibody or NGPCR ligand fusion protein. The solid phase support may then be washed with the buffer a second time to remove unbound antibody or fusion protein. The amount of bound label on solid support may then be detected by conventional means.

[098] By "solid phase support or carrier" is intended any support capable of binding an antigen or an antibody. Well-known supports or carriers include glass, polystyrene, polypropylene, polyethylene, dextran, nylon, amyloses, natural and modified celluloses, polyacrylamides, gabbros, and magnetite. The nature of the carrier can be either soluble to some extent or insoluble for the purposes of the present invention. The support material can have virtually any possible structural configuration so long as the coupled molecule is capable of binding to an antigen or antibody. Thus, the support configuration may be spherical, as in a bead, or cylindrical, as in the inside surface of a test tube, or the external surface of a rod. Alternatively, the surface may be flat such as a sheet, test strip, etc. Preferred supports include polystyrene beads.

Those skilled in the art will know many other suitable carriers for binding antibody or antigen, or will be able to ascertain the same by use of routine experimentation.

[0099] The binding activity of a given lot of NGPCR antibody or NGPCR ligand fusion protein may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.

[0100] With respect to antibodies, one of the ways in which the NGPCR antibody can be detectably labeled is by linking the same to an enzyme and use in an enzyme immunoassay (EIA) (Voller, A., "The Enzyme Linked Immunosorbent Assay (ELISA)", 1978, Diagnostic Horizons 2:1-7, Microbiological Associates Quarterly Publication, Walkersville, MD); Voller, A. et al., 1978, J. Clin. Pathol. 31:507-520; Butler, J.E., 1981, Meth. Enzymol. 73:482-523; Maggio, E. (ed.), 1980, Enzyme Immunoassay, CRC Press, Boca Raton, FL.; Ishikawa, E. et al., (eds.), 1981, Enzyme Immunoassay, Kigaku Shoin, Tokyo). The enzyme that is bound to the antibody will react with an appropriate substrate, preferably a chromogenic substrate, in such a manner as to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorimetric or by visual means. Enzymes which can be used to detectably label the antibody include, but are not limited to, malate dehydrogenase, staphylococcal nuclease, delta-5-steroid isomerase, yeast alcohol dehydrogenase, alpha-glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, beta-galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase. The detection can be accomplished by colorimetric methods

which employ a chromogenic substrate for the enzyme. Detection may also be accomplished by visual comparison of the extent of enzymatic reaction of a substrate in comparison with similarly prepared standards.

[0101] Detection may also be accomplished using any of a variety of other immunoassays. For example, by radioactively labeling the antibodies or antibody fragments, it is possible to detect NGPCR through the use of a radioimmunoassay (RIA) (see, for example, Weintraub, B., Principles of Radioimmunoassays, Seventh Training Course on Radioligand Assay Techniques, The Endocrine Society, March, 1986, which is incorporated by reference herein). The radioactive isotope can be detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.

[0102] It is also possible to label the antibody with a fluorescent compound. When the fluorescently labeled antibody is exposed to light of the proper wave length, its presence can then be detected due to fluorescence. Among the most commonly used fluorescent labeling compounds are fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine.

[0103] The antibody can also be detectably labeled using fluorescence emitting metals such as ^{152}Eu , or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA).

[0104] The antibody also can be detectably labeled by coupling it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antibody is then determined by detecting the presence of luminescence that arises during the course of a chemical reaction. Examples of particularly useful chemiluminescent

labeling compounds are luminol, isoluminol, thermotropic acridinium ester, imidazole, acridinium salt and oxalate ester.

[0105] Likewise, a bioluminescent compound may be used to label the antibody of the present invention. Bioluminescence is a type of chemiluminescence found in biological systems in, which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence. Important bioluminescent compounds for purposes of labeling are luciferin, luciferase and aequorin.

SCREENING ASSAYS FOR COMPOUNDS THAT MODULATE NGPCR EXPRESSION OR ACTIVITY

[0106] The following assays are designed to identify compounds that interact with (e.g., bind to) NGPCRs (including, but not limited to an ECD or CD of a NGPCR), compounds that interact with (e.g., bind to) intracellular proteins that interact with NGPCR (including but not limited to the TM and CD of NGPCR), compounds that interfere with the interaction of NGPCR with transmembrane or intracellular proteins involved in NGPCR-mediated signal transduction, and to compounds which modulate the activity of NGPCR gene (*i.e.*, modulate the level of NGPCR gene expression) or modulate the level of NGPCR. Assays may additionally be utilized which identify compounds which bind to NGPCR gene regulatory sequences (e.g., promoter sequences) and which may modulate NGPCR gene expression. See e.g., Platt, K.A., 1994, J. Biol. Chem. 269:28558-28562, which is incorporated herein by reference in its entirety.

[0107] The compounds that can be screened in accordance with the invention include but are not limited to peptides, antibodies and fragments thereof, and other

organic compounds (e.g., peptidomimetics) that bind to an ECD of a NGPCR and either mimic the activity triggered by the natural ligand (i.e., agonists) or inhibit the activity triggered by the natural ligand (i.e., antagonists); as well as peptides, antibodies or fragments thereof, and other organic compounds that mimic the ECD of the NGPCR (or a portion thereof) and bind to and "neutralize" the natural ligand.

[0108] Such compounds may include, but are not limited to, peptides such as, for example, soluble peptides, including but not limited to members of random peptide libraries; (see, e.g., Lam, K.S. et al., 1991, Nature 354:82-84; Houghten, R. et al., 1991, Nature 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not limited to members of random or partially degenerate, directed phosphopeptide libraries; see, e.g., Songyang, Z. et al., 1993, Cell 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂ and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

[0109] Other compounds which can be screened in accordance with the invention include but are not limited to small organic molecules that are able to cross the blood-brain barrier, gain entry into an appropriate cell (e.g., in the cerebellum, the hypothalamus, etc.) and affect the expression of a NGPCR gene or some other gene involved in the NGPCR signal transduction pathway (e.g., by interacting with the regulatory region or transcription factors involved in gene expression); or such compounds that affect the activity of the NGPCR (e.g., by inhibiting or enhancing the

enzymatic activity of a CD) or the activity of some other intracellular factor involved in the NGPCR signal transduction pathway.

[0110] Computer modeling and searching technologies permit identification of compounds, or the improvement of already identified compounds, that can modulate NGPCR expression or activity. Having identified such a compound or composition, the active sites or regions are identified. Such active sites might typically be ligand binding sites. The active site can be identified using methods known in the art including, for example, from the amino acid sequences of peptides, from the nucleotide sequences of nucleic acids, or from study of complexes of the relevant compound or composition with its natural ligand. In the latter case, chemical or X-ray crystallographic methods can be used to find the active site by finding where on the factor the complexed ligand is found.

[0111] Next, the three dimensional geometric structure of the active site is determined. This can be done by known methods, including X-ray crystallography, which can determine a complete molecular structure. On the other hand, solid or liquid phase NMR can be used to determine certain intra-molecular distances. Any other experimental method of structure determination can be used to obtain partial or complete geometric structures. The geometric structures may be measured with a complexed ligand, natural or artificial, which may increase the accuracy of the active site structure determined.

[0112] If an incomplete or insufficiently accurate structure is determined, the methods of computer based numerical modeling can be used to complete the structure or improve its accuracy. Any recognized modeling method may be used, including parameterized models specific to particular biopolymers such as proteins or nucleic

acids, molecular dynamics models based on computing molecular motions, statistical mechanics models based on thermal ensembles, or combined models. For most types of models, standard molecular force fields, representing the forces between constituent atoms and groups, are necessary, and can be selected from force fields known in physical chemistry. The incomplete or less accurate experimental structures can serve as constraints on the complete and more accurate structures computed by these modeling methods.

[0113] Finally, having determined the structure of the active site, either experimentally, by modeling, or by a combination, candidate modulating compounds can be identified by searching databases containing compounds along with information on their molecular structure. Such a search seeks compounds having structures that match the determined active site structure and that interact with the groups defining the active site. Such a search can be manual, but is preferably computer assisted. These compounds found from this search are potential NGPCR modulating compounds.

[0114] Alternatively, these methods can be used to identify improved modulating compounds from an already known modulating compound or ligand. The composition of the known compound can be modified and the structural effects of modification can be determined using the experimental and computer modeling methods described above applied to the new composition. The altered structure is then compared to the active site structure of the compound to determine if an improved fit or interaction results. In this manner systematic variations in composition, such as by varying side groups, can be quickly evaluated to obtain modified modulating compounds or ligands of improved specificity or activity.

[0115] Further experimental and computer modeling methods useful to identify modulating compounds based upon identification of the active sites of a NGPCR, and related transduction and transcription factors will be apparent to those of skill in the art.

[0116] Examples of molecular modeling systems are the CHARMM and QUANTA programs (Polygen Corporation, Waltham, MA). CHARMM performs the energy minimization and molecular dynamics functions. QUANTA performs the construction, graphic modeling and analysis of molecular structure. QUANTA allows interactive construction, modification, visualization, and analysis of the behavior of molecules with each other.

[0117] A number of articles review computer modeling of drugs interactive with specific proteins, such as Rotivinen, et al., 1988, Acta Pharmaceutica Fennica 97:159-166; Ripka, New Scientist 54-57 (June 16, 1988); McKinaly and Rossmann, 1989, Annu. Rev. Pharmacol. Toxicol. 29:111-122; Perry and Davies, OSAR: Quantitative Structure-Activity Relationships in Drug Design pp. 189-193 (Alan R. Liss, Inc. 1989); Lewis and Dean, 1989 Proc. R. Soc. Lond. 236:125-140 and 141-162; and, with respect to a model receptor for nucleic acid components, Askew, et al., 1989, J. Am. Chem. Soc. 111:1082-1090. Other computer programs that screen and graphically depict chemicals are available from companies such as BioDesign, Inc. (Pasadena, CA.), Allelix, Inc. (Mississauga, Ontario, Canada), and Hypercube, Inc. (Cambridge, Ontario). Although these are primarily designed for application to drugs specific to particular proteins, they can be adapted to design of drugs specific to regions of DNA or RNA, once that region is identified.

[0118] Although described above with reference to design and generation of compounds which could alter binding, one could also screen libraries of known compounds, including natural products or synthetic chemicals, and biologically active materials, including proteins, for compounds which are inhibitors or activators.

[0119] Cell-based systems can also be used to identify compounds that bind NGPCRs as well as assess the altered activity associated with such binding in living cells. Assays for agonists and antagonists of NGPCRS that can be used in cell-based systems according to certain embodiments include, but are not limited to, those described in U.S. Patent Serial No. 6,004,808, and PCT Application Number US99/17425, which are herein incorporated by reference in their entirety for any purpose.

[0120] One tool of particular interest for such assays is green fluorescent protein which is described, inter alia, in U.S. Patent No. 5,625,048, herein incorporated by reference. Cells that may be used in such cellular assays include, but are not limited to, leukocytes, or cell lines derived from leukocytes, lymphocytes, stem cells, including embryonic stem cells, and the like. In addition, expression host cells (e.g., B95 cells, COS cells, CHO cells, OMK cells, fibroblasts, Sf9 cells) genetically engineered to express a functional NGPCR of interest and to respond to activation by the test, or natural, ligand, as measured by a chemical or phenotypic change, or induction of another host cell gene, can be used as an end point in the assay.

[0121] Compounds identified via assays such as those described herein may be useful, for example, in elaborating certain biological functions of a NGPCR gene product. Such compounds can be administered to a patient at therapeutically effective doses to treat any of a variety of physiological or mental disorders. A therapeutically

effective dose refers to that amount of the compound sufficient to result in any amelioration, impediment, prevention, or alteration of any biological or overt symptom.

[0122] Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, typically care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

[0123] The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

[0124] Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral, intracranial, intrathecal, or rectal administration.

[0125] For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

[0126] Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

[0127] For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0128] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0129] The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0130] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0131] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0132] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

IN VITRO SCREENING ASSAYS FOR COMPOUNDS THAT BIND TO NGPCRs

[0133] In vitro systems may be designed to identify compounds capable of interacting with (e.g., binding to) NGPCR (including, but not limited to, a ECD or CD of NGPCR). Compounds identified may be useful, for example, in modulating the activity of wild type and/or mutant NGPCR gene products; may be useful in elaborating certain biological functions of the NGPCR; may be utilized in screens for identifying compounds that disrupt normal NGPCR interactions; or may in themselves disrupt such interactions.

[0134] The principle of the assays used to identify compounds that bind to the NGPCR involves preparing a reaction mixture of the NGPCR and the test compound under conditions and for a time sufficient to allow the two components to interact and bind, thus forming a complex which can be removed and/or detected in the reaction mixture. The NGPCR species used can vary depending upon the goal of the screening

assay. For example, in certain embodiments, where agonists of the natural ligand are sought, the full length NGPCR, or a soluble truncated NGPCR, e.g., in which the TM and/or CD is deleted from the molecule, a peptide corresponding to a ECD or a fusion protein containing one or more NGPCR ECD fused to a protein or polypeptide that affords advantages in the assay system (e.g., labeling, isolation of the resulting complex, etc.) can be utilized. Where compounds that interact with the cytoplasmic domain are sought to be identified, peptides corresponding to the NGPCR CD and fusion proteins containing the NGPCR CD can be used.

[0135] The screening assays can be conducted in a variety of ways. For example, one method to conduct such an assay would involve anchoring the NGPCR protein, polypeptide, peptide or fusion protein or the test substance onto a solid phase and detecting NGPCR/test compound complexes anchored on the solid phase at the end of the reaction. In certain embodiments of such a method, the NGPCR reactant may be anchored onto a solid surface, and the test compound, which is not anchored, may be labeled, either directly or indirectly.

[0136] In practice, microtiter plates may conveniently be utilized as the solid phase. The anchored component may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished by simply coating the solid surface with a solution of the protein and drying. Alternatively, an immobilized antibody, preferably a monoclonal antibody, specific for the protein to be immobilized may be used to anchor the protein to the solid surface. The surfaces may be prepared in advance and stored.

[0137] In order to conduct the assay, the nonimmobilized component is added to the coated surface containing the anchored component. After the reaction is complete, unreacted components are removed (e.g., by washing) under conditions such that any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the previously nonimmobilized component is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the previously nonimmobilized component is not pre-labeled, an indirect label can be used to detect complexes anchored on the surface; e.g., using a labeled antibody specific for the previously nonimmobilized component (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody).

[0138] Alternatively, a reaction can be conducted in a liquid phase, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for a NGPCR protein, polypeptide, peptide or fusion protein or the test compound to anchor any complexes formed in solution, and a labeled antibody specific for the other component of the possible complex to detect anchored complexes.

[0139] Alternatively, cell-based assays can be used to identify compounds that interact with NGPCR. To this end, cell lines that express NGPCR, or cell lines (e.g., COS cells, CHO cells, fibroblasts, etc.) that have been genetically engineered to express a NGPCR (e.g., by transfection or transduction of NGPCR DNA) can be used. Interaction of the test compound with, for example, a ECD of a NGPCR expressed by the host cell can be determined by comparison or competition with native ligand.

5.5.2. ASSAYS FOR INTRACELLULAR PROTEINS THAT INTERACT WITH NGPCRS

[0140] Any method suitable for detecting protein-protein interactions may be employed for identifying transmembrane proteins or intracellular proteins that interact with a NGPCR. Among the traditional methods which may be employed are co-immunoprecipitation, crosslinking and co-purification through gradients or chromatographic columns of cell lysates or proteins obtained from cell lysates and a NGPCR to identify proteins in the lysate that interact with the NGPCR. For these assays, the NGPCR component used can be a full length NGPCR, a soluble derivative lacking the membrane-anchoring region (e.g., a truncated NGPCR in which a TM is deleted resulting in a truncated molecule containing a ECD fused to a CD), a peptide corresponding to a CD or a fusion protein containing a CD of a NGPCR. Once isolated, such an intracellular protein can be identified and can, in turn, be used, in conjunction with standard techniques, to identify proteins with which it interacts. For example, at least a portion of the amino acid sequence of an intracellular protein which interacts with a NGPCR can be ascertained using techniques well known to those of skill in the art, such as via the Edman degradation technique. (See, e.g., Creighton, 1983, "Proteins: Structures and Molecular Principles", W.H. Freeman & Co., N.Y., pp.34-49). The amino acid sequence obtained may be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for gene sequences encoding such intracellular proteins. Screening can be accomplished, for example, by standard hybridization or PCR techniques. Techniques for the generation of oligonucleotide mixtures and the screening are well-known. (See, e.g., Ausubel, supra, and PCR Protocols: A Guide to Methods and Applications, 1990, Innis, M. et al., eds. Academic Press, Inc., New York).

[0141] Additionally, methods may be employed which result in the simultaneous identification of genes which encode the transmembrane or intracellular proteins interacting with NGPCR. These methods include, for example, probing expression, libraries, in a manner similar to the well known technique of antibody probing of λ gt11 libraries, using labeled NGPCR protein, or an NGPCR polypeptide, peptide or fusion protein, e.g., an NGPCR polypeptide or NGPCR domain fused to a marker (e.g., an enzyme, fluor, luminescent protein, or dye), or an Ig-Fc domain.

[0142] One method that detects protein interactions in vivo, the two-hybrid system, is described in detail for illustration only and not by way of limitation. One version of this system has been described (Chien et al., 1991, Proc. Natl. Acad. Sci. USA, 88:9578-9582) and is commercially available from Clontech (Palo Alto, CA).

[0143] Briefly, utilizing such a system, plasmids are constructed that encode two hybrid proteins: one plasmid has nucleotides encoding the DNA-binding domain of a transcription activator protein fused to a NGPCR nucleotide sequence encoding NGPCR, an NGPCR polypeptide, peptide or fusion protein, and the other plasmid has nucleotides encoding the transcription activator protein's activation domain fused to a cDNA encoding an unknown protein which has been recombined into this plasmid as part of a cDNA library. The DNA-binding domain fusion plasmid and the cDNA library are transformed into a strain of the yeast *Saccharomyces cerevisiae* that contains a reporter gene (e.g., HBS or lacZ) whose regulatory region contains the transcription activator's binding site. Either hybrid protein alone cannot activate transcription of the reporter gene: the DNA-binding domain hybrid cannot because it does not provide activation function and the activation domain hybrid cannot because it cannot localize to

the activator's binding sites. Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter gene, which is detected by an assay for the reporter gene product.

[0144] The two-hybrid system or related methodology may be used to screen activation domain libraries for proteins that interact with the "bait" gene product. By way of example, and not by way of limitation, a NGPCR may be used as the bait gene product. Total genomic or cDNA sequences are fused to the DNA encoding an activation domain. This library and a plasmid encoding a hybrid of a bait NGPCR gene product fused to the DNA-binding domain are cotransformed into a yeast reporter strain, and the resulting transformants are screened for those that express the reporter gene. For example, and not by way of limitation, a bait NGPCR gene sequence, such as the open reading frame of a NGPCR (or a domain of a NGPCR) can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein. These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids.

[0145] A cDNA library of the cell line from which proteins that interact with bait NGPCR gene product are to be detected can be made using methods routinely practiced in the art. According to certain embodiments of the system described herein, for example, the cDNA fragments can be inserted into a vector such that they are translationally fused to the transcriptional activation domain of GAL4. This library can be co-transformed along with the bait NGPCR gene-GAL4 fusion plasmid into a yeast strain which contains a lacZ gene driven by a promoter which contains GAL4 activation

sequence. A cDNA encoded protein, fused to GAL4 transcriptional activation domain, that interacts with bait NGPCR gene product will reconstitute an active GAL4 protein and thereby drive expression of the HIS3 gene. Colonies which express HIS3 can be detected by their growth on petri dishes containing semi-solid agar based media lacking histidine. The cDNA can then be purified from these strains, and used to produce and isolate the bait NGPCR gene-interacting protein using techniques routinely practiced in the art.

ASSAYS FOR COMPOUNDS THAT INTERFERE WITH NGPCR/INTRACELLULAR
OR NGPCR/TRANSMEMBRANE MACROMOLECULE INTERACTION

[0146] The macromolecules that interact with the NGPCR are referred to, for purposes of this discussion, as "binding partners." These binding partners are likely to be involved in the NGPCR signal transduction pathway. Therefore, it is desirable to identify compounds that interfere with or disrupt the interaction of such binding partners which may be useful in regulating the activity of a NGPCR and controlling disorders associated with NGPCR activity. For example, given their expression pattern, the described NGPCRs are contemplated to be particularly useful in methods for identifying compounds useful in the therapeutic treatment of obesity, inflammation, immune disorders, diabetes, heart and coronary disease, metabolic disorders, and cancer.

[0147] The basic principle of the assay systems used to identify compounds that interfere with the interaction between a NGPCR and its binding partner or partners involves preparing a reaction mixture containing NGPCR protein, polypeptide, peptide or fusion protein as described in Sections 5.5.1 and 5.5.2 above, and the binding partner under conditions and for a time sufficient to allow the two to interact and bind,

thus forming a complex. In order to test a compound for inhibitory activity, the reaction mixture is prepared in the presence and absence of the test compound. The test compound may be initially included in the reaction mixture, or may be added at a time subsequent to the addition of the NGPCR moiety and its binding partner. Control reaction mixtures are incubated without the test compound or with a placebo. The formation of any complexes between the NGPCR moiety and the binding partner is then detected. The formation of a complex in the control reaction, but not in the reaction mixture containing the test compound, indicates that the compound interferes with the interaction of the NGPCR and the interactive binding partner. Additionally, complex formation within reaction mixtures containing the test compound and normal NGPCR protein may also be compared to complex formation within reaction mixtures containing the test compound and a mutant NGPCR. This comparison may be important in those cases wherein it is desirable to identify compounds that specifically disrupt interactions of mutant, or mutated, NGPCRs but not normal NGPCRs.

[0148] According to certain embodiments, the assay for compounds that interfere with the interaction of a NGPCR and its binding partners can be conducted in a heterogeneous or homogeneous format. Heterogeneous assays involve anchoring either the NGPCR moiety product or the binding partner onto a solid phase and detecting complexes anchored on the solid phase at the end of the reaction. In homogeneous assays, the entire reaction is carried out in a liquid phase. In either approach, the order of addition of reactants can be varied to obtain different information about the compounds being tested. For example, test compounds that interfere with the interaction by competition can be identified by conducting the reaction in the presence

of the test substance; i.e., by adding the test substance to the reaction mixture prior to, or simultaneously with, a NGPCR moiety and interactive binding partner. Alternatively, test compounds that disrupt preformed complexes, e.g. compounds with higher binding constants that displace one of the components from the complex, can be tested by adding the test compound to the reaction mixture after complexes have been formed. Various formats, according to certain embodiments, are described briefly below.

[0149] In a heterogeneous assay system, either a NGPCR moiety or an interactive binding partner, is anchored onto a solid surface, while the non-anchored species is labeled, either directly or indirectly. In practice, microtiter plates are conveniently utilized. The anchored species may be immobilized by non-covalent or covalent attachments. Non-covalent attachment may be accomplished simply by coating the solid surface with a solution of the NGPCR gene product or binding partner and drying. Alternatively, an immobilized antibody specific for the species to be anchored may be used to anchor the species to the solid surface. The surfaces may be prepared in advance and stored.

[0150] In order to conduct the assay, the partner of the immobilized species is exposed to the coated surface with or without the test compound. After the reaction is complete, unreacted components are removed (e.g., by washing) and any complexes formed will remain immobilized on the solid surface. The detection of complexes anchored on the solid surface can be accomplished in a number of ways. Where the non-immobilized species is pre-labeled, the detection of label immobilized on the surface indicates that complexes were formed. Where the non-immobilized species is not pre-labeled, an indirect label can be used to detect complexes anchored on the

surface; e.g., using a labeled antibody specific for the initially non-immobilized species (the antibody, in turn, may be directly labeled or indirectly labeled with a labeled anti-Ig antibody). Depending upon the order of addition of reaction components, test compounds which inhibit complex formation or which disrupt preformed complexes can be detected.

[0151] Alternatively, the reaction can be conducted in a liquid phase in the presence or absence of the test compound, the reaction products separated from unreacted components, and complexes detected; e.g., using an immobilized antibody specific for one of the binding components to anchor any complexes formed in solution, and a labeled antibody specific for the other partner to detect anchored complexes. Again, depending upon the order of addition of reactants to the liquid phase, test compounds which inhibit complex or which disrupt preformed complexes can be identified.

[0152] In certain embodiments of the invention, a homogeneous assay can be used in which a preformed complex of a NGPCR moiety and an interactive binding partner is prepared in which either the NGPCR or its binding partner is labeled, but the signal generated by the label is quenched due to formation of the complex (see, e.g., U.S. Patent No. 4,109,496 by Rubenstein which utilizes this approach for immunoassays). The addition of a test substance that competes with and displaces one of the species from the preformed complex will result in the generation of a signal above background. In this way, test substances which disrupt NGPCR/intracellular binding partner interaction can be identified.

[0153] In certain embodiments, a NGPCR fusion can be prepared for immobilization. For example, a NGPCR or a peptide fragment, e.g., corresponding to a CD, can be fused to a glutathione-S-transferase (GST) gene using a fusion vector, such as pGEX-5X-1, in such a manner that its binding activity is maintained in the resulting fusion protein. The interactive binding partner can be purified and used to raise a monoclonal antibody, using methods routinely practiced in the art and described above, in Section 5.3. This antibody can be labeled with the radioactive isotope ^{125}I , for example, by methods routinely practiced in the art. In a heterogeneous assay, e.g., the GST-NGPCR fusion protein can be anchored to glutathione-agarose beads. The interactive binding partner can then be added in the presence or absence of the test compound in a manner that allows interaction and binding to occur. At the end of the reaction period, unbound material can be washed away, and the labeled monoclonal antibody can be added to the system and allowed to bind to the complexed components. The interaction between a NGPCR gene product and the interactive binding partner can be detected by measuring the amount of radioactivity that remains associated with the glutathione-agarose beads. A successful inhibition of the interaction by the test compound will result in a decrease in measured radioactivity.

[0154] Alternatively, the GST-NGPCR fusion protein and the interactive binding partner can be mixed together in liquid in the absence of the solid glutathione-agarose beads. The test compound can be added either during or after the species are allowed to interact. This mixture can then be added to the glutathione-agarose beads and unbound material is washed away. Again the extent of inhibition of the NGPCR/binding

partner interaction can be detected by adding the labeled antibody and measuring the radioactivity associated with the beads.

[0155] In certain embodiments of the invention, these same techniques can be employed using peptide fragments that correspond to the binding domains of a NGPCR and/or the interactive or binding partner (in cases where the binding partner is a protein), in place of one or both of the full length proteins. Any number of methods routinely practiced in the art can be used to identify and isolate the binding sites. These methods include, but are not limited to, mutagenesis of the gene encoding one of the proteins and screening for disruption of binding in a co-immunoprecipitation assay. Compensatory mutations in the gene encoding the second species in the complex can then be selected. Sequence analysis of the genes encoding the respective proteins will reveal the mutations that correspond to the region of the protein involved in interactive binding. Alternatively, one protein can be anchored to a solid surface using methods described above, and allowed to interact with and bind to its labeled binding partner, which has been treated with a proteolytic enzyme, such as trypsin. After washing, a relatively short, labeled peptide comprising the binding domain may remain associated with the solid material, which can be isolated and identified by amino acid sequencing. Also, once the gene coding for the intracellular binding partner is obtained, short gene segments can be engineered to express peptide fragments of the protein, which can then be tested for binding activity and purified or synthesized.

[0156] For example, and not by way of limitation, a NGPCR gene product can be anchored to a solid material as described, above, by making a GST-NGPCR fusion protein and allowing it to bind to glutathione agarose beads. The interactive binding

partner can be labeled with a radioactive isotope, such as ^{35}S , and cleaved with a proteolytic enzyme such as trypsin. Cleavage products can then be added to the anchored GST-NGPCR fusion protein and allowed to bind. After washing away unbound peptides, labeled bound material, representing the intracellular binding partner binding domain, can be eluted, purified, and analyzed for amino acid sequence by well-known methods. Peptides so identified can be produced synthetically or fused to appropriate facilitative proteins using recombinant DNA technology.

[0157] The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as illustrations of individual aspects of certain embodiments of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. All referenced publications, patents, and patent applications are incorporated by reference herein for any purpose.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a nucleotide sequence selected from:
 - a) the nucleotide sequence as set forth in SEQ ID NO: 1;
 - b) the nucleotide sequence as set forth in SEQ ID NO: 5;
 - c) the nucleotide sequence as set forth in SEQ ID NO: 7;
 - d) the nucleotide sequence as set forth in SEQ ID NO: 11; and
 - e) the nucleotide sequence as set forth in SEQ ID NO: 19.
2. The isolated nucleic acid molecule of claim 1, comprising a nucleotide sequence as set forth in SEQ ID NO: 5.
3. An isolated nucleic acid molecule comprising at least 300 contiguous bases of a nucleotide sequence selected from:
 - a) the nucleotide sequence as set forth in SEQ ID NO: 1;
 - b) the nucleotide sequence as set forth in SEQ ID NO: 5;
 - c) the nucleotide sequence as set forth in SEQ ID NO: 7;
 - d) the nucleotide sequence as set forth in SEQ ID NO: 11; and
 - e) the nucleotide sequence as set forth in SEQ ID NO: 19.
4. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 6.

5. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 2.
6. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 8.
7. An isolated nucleic acid molecule comprising a nucleotide sequence encoding the amino acid sequence as set forth in SEQ ID NO: 12.
8. An isolated polypeptide comprising an amino acid sequence selected from:
 - a) the amino acid sequence as set forth in SEQ ID NO: 6;
 - b) the amino acid sequence as set forth in SEQ ID NO: 2;
 - c) the amino acid sequence as set forth in SEQ ID NO: 8; and
 - d) the amino acid sequence as set forth in SEQ ID NO: 12.
9. An isolated polypeptide of claim 8, comprising an amino acid sequence as set forth in SEQ ID NO: 6.
10. An isolated polypeptide comprising an amino acid sequence selected from:
 - a) the amino acid sequence as set forth in SEQ ID NO: 6 with at least one conservative amino acid substitution;
 - b) the amino acid sequence as set forth in SEQ ID NO: 2 with at least one conservative amino acid substitution;
 - c) the amino acid sequence as set forth in SEQ ID NO: 8 with at least one conservative amino acid substitution; and

d) the amino acid sequence as set forth in SEQ ID NO: 12 with at least one conservative amino acid substitution.

11. An isolated polypeptide of claim 10, comprising an amino acid sequence as set forth in SEQ ID NO: 6 with at least one conservative amino acid substitution.

12. A recombinant host cell containing an isolated nucleic acid molecule of any of claims 1, 2, 3, 4, 5, 6, or 7.

13. A recombinant host cell of claim 12, wherein the host cell is eukaryotic.

14. A recombinant host cell of claim 13, wherein the host cell is selected from CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, and WI38 cell lines.

SEQUENCE LISTING

<110> Walke, D. Wade
Wang, Xiaoming
Scoville, John

<120> Novel Human Membrane Proteins and Polynucleotides Encoding the Same

<130> 07705.0014-00000

<140> Not yet assigned

<141> April 27, 2001

<150> US 60/199,950

<151> 2000-04-27

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 2310

<212> DNA

<213> homo sapiens

<400> 1

atgaacggac	agttggatct	aagtgggaag	ctaatacatca	aagctcaact	tggggaggat	60
attcggcgaa	ttcctattca	taatgaagat	attacttatg	atgaattagt	gctaatagat	120
caacgagttt	tcagaggaaa	acttctgagt	aatgatgaag	taacaataaa	gtataaagat	180
gaagatggag	atcttataac	aatttttgat	agttctgacc	tttcctttgc	aattcagtg	240
agtaggatac	tgaaactgac	attatttgga	aaatctactt	cctcatcaag	caccctaca	300
gagttctgca	ggaatggtgg	aacctgggaa	aatggcagat	gtatttgtac	agaagagtgg	360
aaaggactga	gatgtacaat	tgctaatttt	tgtgaaaata	gtacctatat	gggttttact	420
tttgccagaa	tcccagtggg	cagatatgga	ccatccttgc	aaacatgtgg	caaggatact	480
ccaaatgcgg	gcaatccaat	ggcagtcogg	ttgtgcagtc	tctctctata	tggagagata	540
gaattacaaa	aagtgacaat	aggaaattgc	aatgaaaatc	tggaaaccct	ggaaaagcag	600
gtaaaggatg	tcacagcacc	acttaataac	atctcttctg	aagtccagat	tttaacatct	660
gatgccaaata	aattaactgc	tgagaacatc	actagtgc	cgcgagtgg	tggacagata	720
ttcaacactt	ccagaaatgc	ttcacctgag	gcaaagaaag	ttgccatagt	aacagtga	780
caactcctag	atgccagtga	agatgctttt	caaagagttg	ctgctactgc	taatgatgat	840
gcccttacaa	cgcttattga	gcaaattggag	acttattcct	tgtctttggg	taatcaatca	900
gtggtggaac	ctaacatagc	aatacagtc	gcaaatttct	cttcagaaaa	tgcgggtggg	960
ccttcaaagt	ttcgcttctc	tgtgcagaaa	ggagctagca	gttctctagt	ttctagttca	1020
acattttatac	atacaaatgt	ggatggcctt	aaccagatg	cacagactga	gcttcaggtc	1080
ttgcttaata	tgacgaaaaa	ttacaccaag	acatgcggct	ttgtagttta	tcaaaatgac	1140
aagctttttcc	aatcaaaaaa	ttttacagct	aaatcggatt	ttagtcaaaa	aattatctca	1200
agcaaaactg	atgaaaaatga	gcaagatcag	agtgcctctg	ttgacatgg	ctttagtcca	1260
aagtacaacc	aaaaagaatt	tcaactctat	tcctatgcct	gtgtctattg	gaatttgtca	1320
gcgaaggact	gggacacata	tggctgtcaa	aaagacaagg	gcaactgatg	attcctg	1380
tgccgctgca	accatactac	taattttgct	gtattaatga	ctttcaaaaa	ggattatcaa	1440
tatcccaaat	cacttgacat	attatccaac	gttggatgtg	caactgtctg	tactggtctg	1500
gctctcacag	ttataatttca	gattgtcacc	aggaaagtca	gaaaaacctc	agtaacctgg	1560
gttttggtca	atctgtgcat	atcaatgttg	attttcaacc	tcctctttgt	gtttggaatt	1620
gaaaactcca	ataagaactt	gcagacaagt	gatggtgaca	tcaataatat	tgactttgac	1680
aataatgaca	taccaggac	agacaccatt	aacatcccga	atcccatgtg	caactgcgatt	1740
gccgccttac	tgcactattt	tctgttagtg	acatttacct	ggaacgcact	cagcgctgca	1800
cagctctatt	accttcta	aaggaccatg	aagcctcttc	ctcggcattt	cattcttttc	1860
atctcattaa	ttggatgggg	agtcacagct	atagtagtgg	ctataacagt	gggagttatt	1920
tatttctcaga	atgggaaata	tccacagtgg	gaattagact	accggcaaga	gaaaatctgc	1980
tggctggcaa	ttccagaacc	caatggtgtt	ataaaaagtc	cgctgtgtgtg	gtcattcatc	2040
gtacctgtaa	ccattatcct	catcagcaat	gttggttatgt	ttattacaat	ctcgatcaaa	2100

```

gtgctgtgga agaataacca gaacctgaca agcacaaaaa aagtttcatc catgaagaag 2160
attgtagca cattatctgt tgcagttgtt tttggaatta cctggattct agcatacctg 2220
atgctagtta atgatgatag catcaggatc gtcttcagct acatattctg ccttttcaac 2280
actacacagg tatggtgcgg attagtctga 2310

```

<210> 2

<211> 769

<212> PRT

<213> homo sapiens

<400> 2

```

Met Asn Gly Gln Leu Asp Leu Ser Gly Lys Leu Ile Ile Lys Ala Gln
 1          5          10          15
Leu Gly Glu Asp Ile Arg Arg Ile Pro Ile His Asn Glu Asp Ile Thr
 20          25          30
Tyr Asp Glu Leu Val Leu Met Met Gln Arg Val Phe Arg Gly Lys Leu
 35          40          45
Leu Ser Asn Asp Glu Val Thr Ile Lys Tyr Lys Asp Glu Asp Gly Asp
 50          55          60
Leu Ile Thr Ile Phe Asp Ser Ser Asp Leu Ser Phe Ala Ile Gln Cys
 65          70          75          80
Ser Arg Ile Leu Lys Leu Thr Leu Phe Gly Lys Ser Thr Ser Ser Ser
 85          90          95
Ser Thr Pro Thr Glu Phe Cys Arg Asn Gly Gly Thr Trp Glu Asn Gly
100          105          110
Arg Cys Ile Cys Thr Glu Glu Trp Lys Gly Leu Arg Cys Thr Ile Ala
115          120          125
Asn Phe Cys Glu Asn Ser Thr Tyr Met Gly Phe Thr Phe Ala Arg Ile
130          135          140
Pro Val Gly Arg Tyr Gly Pro Ser Leu Gln Thr Cys Gly Lys Asp Thr
145          150          155          160
Pro Asn Ala Gly Asn Pro Met Ala Val Arg Leu Cys Ser Leu Ser Leu
165          170          175
Tyr Gly Glu Ile Glu Leu Gln Lys Val Thr Ile Gly Asn Cys Asn Glu
180          185          190
Asn Leu Glu Thr Leu Glu Lys Gln Val Lys Asp Val Thr Ala Pro Leu
195          200          205
Asn Asn Ile Ser Ser Glu Val Gln Ile Leu Thr Ser Asp Ala Asn Lys
210          215          220
Leu Thr Ala Glu Asn Ile Thr Ser Ala Thr Arg Val Val Gly Gln Ile
225          230          235          240
Phe Asn Thr Ser Arg Asn Ala Ser Pro Glu Ala Lys Lys Val Ala Ile
245          250          255
Val Thr Val Ser Gln Leu Leu Asp Ala Ser Glu Asp Ala Phe Gln Arg
260          265          270
Val Ala Ala Thr Ala Asn Asp Asp Ala Leu Thr Thr Leu Ile Glu Gln
275          280          285
Met Glu Thr Tyr Ser Leu Ser Leu Gly Asn Gln Ser Val Val Glu Pro
290          295          300
Asn Ile Ala Ile Gln Ser Ala Asn Phe Ser Ser Glu Asn Ala Val Gly
305          310          315          320
Pro Ser Asn Val Arg Phe Ser Val Gln Lys Gly Ala Ser Ser Ser Leu
325          330          335
Val Ser Ser Ser Thr Phe Ile His Thr Asn Val Asp Gly Leu Asn Pro
340          345          350
Asp Ala Gln Thr Glu Leu Gln Val Leu Leu Asn Met Thr Lys Asn Tyr
355          360          365
Thr Lys Thr Cys Gly Phe Val Val Tyr Gln Asn Asp Lys Leu Phe Gln
370          375          380
Ser Lys Thr Phe Thr Ala Lys Ser Asp Phe Ser Gln Lys Ile Ile Ser
385          390          395          400
Ser Lys Thr Asp Glu Asn Glu Gln Asp Gln Ser Ala Ser Val Asp Met

```

```
<210> 3
<211> 891
<212> DNA
<213> homo sapiens
```

3

gaattacaaa	aagtgacaat	aggaaattgc	aatgaaaatc	tggaaccct	ggaaaagcag	600
gtaaaggatg	tcacagcacc	acttaataac	atttcttctg	aagtccagat	tttaacatct	660
gatgccaaata	aattaactgc	tgagaacatc	actagtgc	cgcgagtgg	tggaacagata	720
ttcaacactt	ccagaaatgc	ttcacctgag	gcaaagaaag	ttgccatagt	aacagtgc	780
caactcctag	atgccagtga	agatgctttt	caaagagttg	ctgctactgc	taatgatgat	840
gcccttacaa	cattacacca	agacatgcgg	ctttgtagtt	tatcaaaatg	a	891

<210> 4

<211> 296

<212> PRT

<213> homo sapiens

<400> 4

Met	Asn	Gly	Gln	Leu	Asp	Leu	Ser	Gly	Lys	Leu	Ile	Ile	Lys	Ala	Gln
1				5					10					15	
Leu	Gly	Glu	Asp	Ile	Arg	Arg	Ile	Pro	Ile	His	Asn	Glu	Asp	Ile	Thr
			20					25					30		
Tyr	Asp	Glu	Leu	Val	Leu	Met	Met	Gln	Arg	Val	Phe	Arg	Gly	Lys	Leu
	35					40					45				
Leu	Ser	Asn	Asp	Glu	Val	Thr	Ile	Lys	Tyr	Lys	Asp	Glu	Asp	Gly	Asp
	50					55					60				
Leu	Ile	Thr	Ile	Phe	Asp	Ser	Ser	Asp	Leu	Ser	Phe	Ala	Ile	Gln	Cys
65				70					75					80	
Ser	Arg	Ile	Leu	Lys	Leu	Thr	Leu	Phe	Gly	Lys	Ser	Thr	Ser	Ser	Ser
			85					90					95		
Ser	Thr	Pro	Thr	Glu	Phe	Cys	Arg	Asn	Gly	Gly	Thr	Trp	Glu	Asn	Gly
	100							105					110		
Arg	Cys	Ile	Cys	Thr	Glu	Glu	Trp	Lys	Gly	Leu	Arg	Cys	Thr	Ile	Ala
	115						120					125			
Asn	Phe	Cys	Glu	Asn	Ser	Thr	Tyr	Met	Gly	Phe	Thr	Phe	Ala	Arg	Ile
130						135					140				
Pro	Val	Gly	Arg	Tyr	Gly	Pro	Ser	Leu	Gln	Thr	Cys	Gly	Lys	Asp	Thr
145					150					155				160	
Pro	Asn	Ala	Gly	Asn	Pro	Met	Ala	Val	Arg	Leu	Cys	Ser	Leu	Ser	Leu
			165					170					175		
Tyr	Gly	Glu	Ile	Glu	Leu	Gln	Lys	Val	Thr	Ile	Gly	Asn	Cys	Asn	Glu
		180					185					190			
Asn	Leu	Glu	Thr	Leu	Glu	Lys	Gln	Val	Lys	Asp	Val	Thr	Ala	Pro	Leu
	195					200					205				
Asn	Asn	Ile	Ser	Ser	Glu	Val	Gln	Ile	Leu	Thr	Ser	Asp	Ala	Asn	Lys
	210					215					220				
Leu	Thr	Ala	Glu	Asn	Ile	Thr	Ser	Ala	Thr	Arg	Val	Val	Gly	Gln	Ile
225					230					235				240	
Phe	Asn	Thr	Ser	Arg	Asn	Ala	Ser	Pro	Glu	Ala	Lys	Lys	Val	Ala	Ile
			245					250					255		
Val	Thr	Val	Ser	Gln	Leu	Leu	Asp	Ala	Ser	Glu	Asp	Ala	Phe	Gln	Arg
		260					265					270			
Val	Ala	Ala	Thr	Ala	Asn	Asp	Asp	Ala	Leu	Thr	Thr	Leu	His	Gln	Asp
	275					280					285				
Met	Arg	Leu	Cys	Ser	Leu	Ser	Lys								
	290					295									

<210> 5

<211> 2547

<212> DNA

<213> homo sapiens

<400> 5

atgaacggac	agttggatct	aagtgggaag	ctaatacatca	aagctcaact	tgaggaggat	60
attcggcgaa	ttcctattca	taatgaagat	attacttatg	atgaattagt	gctaattgatg	120
caacgagttt	tcagaggaaa	acttctgagt	aatgatgaag	taacaataaa	gtataaagat	180
gaagatggag	atcittataac	aatttttgat	agttctgacc	tttcctttgc	aattcagtg	240
agtaggatac	tgaaactgac	attatttgga	aaatctactt	cctcatcaag	caccctaca	300

```

gagttctgca ggaatggtgg aacctgggaa aatggcagat gtatttgtac agaagagtgg 360
aaaggactga gatgtacaat tgctaatttt tgtgaaaata gtacctatat ggggttttact 420
tttgccagaa tcccagtggg cagatatgga ccatccttgc aaacatgtgg caaggatact 480
ccaaatgcgg gcaatccaat ggcagtcogg ttgtgcagtc tctctctata tggagagata 540
gaattacaaa aagtgacaat aggaaattgc aatgaaaatc tggaaaccct ggaaaagcag 600
gtaaaggatg tcacagcacc acttaataac atttcttctg aagtccagat tttaacatct 660
gatgccaaata aattaactgc tgagaacatc actagtgcga cgcgagtggg tggacagata 720
ttcaacactt ccagaaatgc ttcacctgag gcaaagaaag ttgccatagt aacagtgaat 780
caactcctag atgccagtga agatgctttt caaagagttg ctgctactgc taatgatgat 840
gcccttacaa cgcttattga gcaaattggag acttattcct tgtctttggg taatcaatca 900
gtggtggaac ctaacatagc aatacagtcg gcaaatttct cttcagaaaa tgcgggtggg 960
ccttcaaagt ttcgcttctc tgtgcagaaa ggagctagca gttctctagt ttctagttca 1020
acatttatac atacaaatgt ggatggcctt aaccagatg cacagactga gcttcaggtc 1080
ttgcttaata tgacgaaaaa ttacaccaag acatgcggct ttgtagttaa tcaaaatgac 1140
aagctttttc aatcaaaaac ttttacagct aaatcgatt ttagtcaaaa aattatctca 1200
agcaaaactg atgaaaatga gcaagatcag agtgcttctg ttgacatggg ctttagtcca 1260
aagtacaacc aaaaagaatt tcaactctat tcctatgcct gtgtctattg gaatttgtca 1320
gcgaaggact gggacacata tggctgtcaa aaagacaagg gcactgatgg attcctgcgc 1380
tgccgctgca accatactac taattttgct gtattaatga ctttcaaaaa ggattatcaa 1440
tatcccaaat cacttgacat attatccaac gttggatgtg cactgtctgt tactggtctg 1500
gctctcacag ttatatattca gattgtcacc aggaaagtca gaaaaacctc agtaacctgg 1560
gttttggcca atctgtgcat atcaatgttg attttcaacc tcctctttgt gtttggatt 1620
gaaaactcca ataagaactt gcagacaagt gatggtgaca tcaataatat tgactttgac 1680
aataatgaca taccaggac agacaccatt aacatcccg atcccatgtg cactgcgatt 1740
gccgccttac tgcactattt tctgttagtg acatttacct ggaacgcact cagecgtgca 1800
cagctctatt accttcta ataggaccatg aagcctcttc ctgcgcattt cattcttttc 1860
atctcattaa ttggatgggg agtcccagct atagtagtgg ctataacagt gggagttatt 1920
tattctcaga atggaataa tccacagtgg gaattagact accggcaaga gaaaatctgc 1980
tggctggcaa ttcagaacc caatggtgtt ataaaaagtc cgctgttggt gtcattcatc 2040
gtacctgtaa ccattatcct catcagcaat gttgttatgt ttattacaat ctcgatcaaa 2100
gtgctgtgga agaataacca gaacctgaca agcacaataa aagtttcatc catgaagaag 2160
attgtaggca cattatctgt tgcagttgtt tttggaatta cctggattct agcatacctg 2220
atgctagtta atgatgatag catcaggatc gtctctcagc acatattctg ccttttcaac 2280
actacacagg atgtgcaaat ttttatcctg tacactgtta gaacaaaagt cttccagagt 2340
gaagcttcca aagtgttgat gttgctatcg tctattggga gaagggaagtc attgccttca 2400
gtgacgcggc cgaggctgcg tgtaaagatg tataatttcc tcagggtcatt gccaacctta 2460
catgaacgct ttaggctact ggaaacctct ccgagtactg aggaaatcac actctctgaa 2520
agtgacaatg caaaggaaa catctag 2547

```

<210> 6

<211> 848

<212> PRT

<213> homo sapiens

<400> 6

```

Met Asn Gly Gln Leu Asp Leu Ser Gly Lys Leu Ile Ile Lys Ala Gln
1          5          10          15
Leu Gly Glu Asp Ile Arg Arg Ile Pro Ile His Asn Glu Asp Ile Thr
20          25          30
Tyr Asp Glu Leu Val Leu Met Met Gln Arg Val Phe Arg Gly Lys Leu
35          40          45
Leu Ser Asn Asp Glu Val Thr Ile Lys Tyr Lys Asp Glu Asp Gly Asp
50          55          60
Leu Ile Thr Ile Phe Asp Ser Ser Asp Leu Ser Phe Ala Ile Gln Cys
65          70          75          80
Ser Arg Ile Leu Lys Leu Thr Leu Phe Gly Lys Ser Thr Ser Ser Ser
85          90          95
Ser Thr Pro Thr Glu Phe Cys Arg Asn Gly Gly Thr Trp Glu Asn Gly
100          105          110
Arg Cys Ile Cys Thr Glu Glu Trp Lys Gly Leu Arg Cys Thr Ile Ala
115          120          125
Asn Phe Cys Glu Asn Ser Thr Tyr Met Gly Phe Thr Phe Ala Arg Ile
130          135          140

```

Pro	Val	Gly	Arg	Tyr	Gly	Pro	Ser	Leu	Gln	Thr	Cys	Gly	Lys	Asp	Thr
145					150					155					160
Pro	Asn	Ala	Gly	Asn	Pro	Met	Ala	Val	Arg	Leu	Cys	Ser	Leu	Ser	Leu
				165					170						175
Tyr	Gly	Glu	Ile	Glu	Leu	Gln	Lys	Val	Thr	Ile	Gly	Asn	Cys	Asn	Glu
			180					185					190		
Asn	Leu	Glu	Thr	Leu	Glu	Lys	Gln	Val	Lys	Asp	Val	Thr	Ala	Pro	Leu
		195					200					205			
Asn	Asn	Ile	Ser	Ser	Glu	Val	Gln	Ile	Leu	Thr	Ser	Asp	Ala	Asn	Lys
	210					215					220				
Leu	Thr	Ala	Glu	Asn	Ile	Thr	Ser	Ala	Thr	Arg	Val	Val	Gly	Gln	Ile
225					230					235					240
Phe	Asn	Thr	Ser	Arg	Asn	Ala	Ser	Pro	Glu	Ala	Lys	Lys	Val	Ala	Ile
				245					250					255	
Val	Thr	Val	Ser	Gln	Leu	Leu	Asp	Ala	Ser	Glu	Asp	Ala	Phe	Gln	Arg
			260					265					270		
Val	Ala	Ala	Thr	Ala	Asn	Asp	Asp	Ala	Leu	Thr	Thr	Leu	Ile	Glu	Gln
		275					280					285			
Met	Glu	Thr	Tyr	Ser	Leu	Ser	Leu	Gly	Asn	Gln	Ser	Val	Val	Glu	Pro
	290					295					300				
Asn	Ile	Ala	Ile	Gln	Ser	Ala	Asn	Phe	Ser	Ser	Glu	Asn	Ala	Val	Gly
305					310					315					320
Pro	Ser	Asn	Val	Arg	Phe	Ser	Val	Gln	Lys	Gly	Ala	Ser	Ser	Ser	Leu
				325					330					335	
Val	Ser	Ser	Ser	Thr	Phe	Ile	His	Thr	Asn	Val	Asp	Gly	Leu	Asn	Pro
			340					345					350		
Asp	Ala	Gln	Thr	Glu	Leu	Gln	Val	Leu	Leu	Asn	Met	Thr	Lys	Asn	Tyr
		355					360					365			
Thr	Lys	Thr	Cys	Gly	Phe	Val	Val	Tyr	Gln	Asn	Asp	Lys	Leu	Phe	Gln
	370					375					380				
Ser	Lys	Thr	Phe	Thr	Ala	Lys	Ser	Asp	Phe	Ser	Gln	Lys	Ile	Ile	Ser
385					390					395					400
Ser	Lys	Thr	Asp	Glu	Asn	Glu	Gln	Asp	Gln	Ser	Ala	Ser	Val	Asp	Met
				405					410					415	
Val	Phe	Ser	Pro	Lys	Tyr	Asn	Gln	Lys	Glu	Phe	Gln	Leu	Tyr	Ser	Tyr
			420					425					430		
Ala	Cys	Val	Tyr	Trp	Asn	Leu	Ser	Ala	Lys	Asp	Trp	Asp	Thr	Tyr	Gly
		435				440						445			
Cys	Gln	Lys	Asp	Lys	Gly	Thr	Asp	Gly	Phe	Leu	Arg	Cys	Arg	Cys	Asn
	450					455					460				
His	Thr	Thr	Asn	Phe	Ala	Val	Leu	Met	Thr	Phe	Lys	Lys	Asp	Tyr	Gln
465					470					475					480
Tyr	Pro	Lys	Ser	Leu	Asp	Ile	Leu	Ser	Asn	Val	Gly	Cys	Ala	Leu	Ser
				485					490					495	
Val	Thr	Gly	Leu	Ala	Leu	Thr	Val	Ile	Phe	Gln	Ile	Val	Thr	Arg	Lys
			500					505					510		
Val	Arg	Lys	Thr	Ser	Val	Thr	Trp	Val	Leu	Val	Asn	Leu	Cys	Ile	Ser
		515					520					525			
Met	Leu	Ile	Phe	Asn	Leu	Leu	Phe	Val	Phe	Gly	Ile	Glu	Asn	Ser	Asn
	530					535					540				
Lys	Asn	Leu	Gln	Thr	Ser	Asp	Gly	Asp	Ile	Asn	Asn	Ile	Asp	Phe	Asp
545					550					555					560
Asn	Asn	Asp	Ile	Pro	Arg	Thr	Asp	Thr	Ile	Asn	Ile	Pro	Asn	Pro	Met
				565					570					575	
Cys	Thr	Ala	Ile	Ala	Ala	Leu	Leu	His	Tyr	Phe	Leu	Leu	Val	Thr	Phe
			580					585					590		
Thr	Trp	Asn	Ala	Leu	Ser	Ala	Ala	Gln	Leu	Tyr	Tyr	Leu	Leu	Ile	Arg
		595					600					605			
Thr	Met	Lys	Pro	Leu	Pro	Arg	His	Phe	Ile	Leu	Phe	Ile	Ser	Leu	Ile
	610					615					620				
Gly	Trp	Gly	Val	Pro	Ala	Ile	Val	Val	Ala	Ile	Thr	Val	Gly	Val	Ile
625					630					635					640
Tyr	Ser	Gln	Asn	Gly	Asn	Asn	Pro	Gln	Trp	Glu	Leu	Asp	Tyr	Arg	Gln

```
<210> 7
<211> 1446
<212> DNA
<213> homo sapiens
```

```
<210> 8
<211> 481
<212> PRT
<213> homo sapiens
```

<400> 8

```

Met Glu Thr Tyr Ser Leu Ser Leu Gly Asn Gln Ser Val Val Glu Pro
 1      5      10      15
Asn Ile Ala Ile Gln Ser Ala Asn Phe Ser Ser Glu Asn Ala Val Gly
      20      25      30
Pro Ser Asn Val Arg Phe Ser Val Gln Lys Gly Ala Ser Ser Ser Leu
      35      40      45
Val Ser Ser Ser Thr Phe Ile His Thr Asn Val Asp Gly Leu Asn Pro
      50      55      60
Asp Ala Gln Thr Glu Leu Gln Val Leu Leu Asn Met Thr Lys Asn Tyr
      65      70      75      80
Thr Lys Thr Cys Gly Phe Val Val Tyr Gln Asn Asp Lys Leu Phe Gln
      85      90      95
Ser Lys Thr Phe Thr Ala Lys Ser Asp Phe Ser Gln Lys Ile Ile Ser
      100      105      110
Ser Lys Thr Asp Glu Asn Glu Gln Asp Gln Ser Ala Ser Val Asp Met
      115      120      125
Val Phe Ser Pro Lys Tyr Asn Gln Lys Glu Phe Gln Leu Tyr Ser Tyr
      130      135      140
Ala Cys Val Tyr Trp Asn Leu Ser Ala Lys Asp Trp Asp Thr Tyr Gly
      145      150      155      160
Cys Gln Lys Asp Lys Gly Thr Asp Gly Phe Leu Arg Cys Arg Cys Asn
      165      170      175
His Thr Thr Asn Phe Ala Val Leu Met Thr Phe Lys Lys Asp Tyr Gln
      180      185      190
Tyr Pro Lys Ser Leu Asp Ile Leu Ser Asn Val Gly Cys Ala Leu Ser
      195      200      205
Val Thr Gly Leu Ala Leu Thr Val Ile Phe Gln Ile Val Thr Arg Lys
      210      215      220
Val Arg Lys Thr Ser Val Thr Trp Val Leu Val Asn Leu Cys Ile Ser
      225      230      235      240
Met Leu Ile Phe Asn Leu Leu Phe Val Phe Gly Ile Glu Asn Ser Asn
      245      250      255
Lys Asn Leu Gln Thr Ser Asp Gly Asp Ile Asn Asn Ile Asp Phe Asp
      260      265      270
Asn Asn Asp Ile Pro Arg Thr Asp Thr Ile Asn Ile Pro Asn Pro Met
      275      280      285
Cys Thr Ala Ile Ala Ala Leu Leu His Tyr Phe Leu Leu Val Thr Phe
      290      295      300
Thr Trp Asn Ala Leu Ser Ala Ala Gln Leu Tyr Tyr Leu Leu Ile Arg
      305      310      315      320
Thr Met Lys Pro Leu Pro Arg His Phe Ile Leu Phe Ile Ser Leu Ile
      325      330      335
Gly Trp Gly Val Pro Ala Ile Val Val Ala Ile Thr Val Gly Val Ile
      340      345      350
Tyr Ser Gln Asn Gly Asn Asn Pro Gln Trp Glu Leu Asp Tyr Arg Gln
      355      360      365
Glu Lys Ile Cys Trp Leu Ala Ile Pro Glu Pro Asn Gly Val Ile Lys
      370      375      380
Ser Pro Leu Leu Trp Ser Phe Ile Val Pro Val Thr Ile Ile Leu Ile
      385      390      395      400
Ser Asn Val Val Met Phe Ile Thr Ile Ser Ile Lys Val Leu Trp Lys
      405      410      415
Asn Asn Gln Asn Leu Thr Ser Thr Lys Lys Val Ser Ser Met Lys Lys
      420      425      430
Ile Val Ser Thr Leu Ser Val Ala Val Val Phe Gly Ile Thr Trp Ile
      435      440      445
Leu Ala Tyr Leu Met Leu Val Asn Asp Asp Ser Ile Arg Ile Val Phe
      450      455      460
Ser Tyr Ile Phe Cys Leu Phe Asn Thr Thr Gln Val Trp Cys Gly Leu
      465      470      475      480
Val

```

<210> 9
 <211> 1272
 <212> DNA
 <213> homo sapiens

<400> 9
 atgccagtga agatgctttt caaagagttg ctgctactgc taatgatgat gccottacaa 60
 cattacacca agacatgcgg cttttagtgg tatcaaaatg acaagctttt ccaatcaaaa 120
 acttttacag ctaaatcgga ttttagtcaa aaaattatct caagcaaaac tgatgaaaat 180
 gagcaagatc agagtgcctc tgttgacatg gtcttttagtc caaagtacaa ccaaaaagaa 240
 tttcaactct attcctatgc ctgtgtctat tggaatttgc cagcgaagga ctgggacaca 300
 tatggctgtc aaaaagacaa gggcactgat ggattcctgc gctgccgctg caaccatact 360
 actaattttg ctgtattaat gactttcaaa aaggattatc aatatcccaa atcacttgac 420
 atattatcca acgttggtg tgcaactgtc gttactggtc tggctctcac agtttatatt 480
 cagattgtca ccaggaaagt cagaaaaacc tcagtaacct gggttttggt caatctgtgc 540
 atatcaatgt tgattttcaa cctcctcttt gtgtttggaa ttgaaaactc caataagaac 600
 ttgcagacaa gtgatggtga catcaataat attgactttg acaataatga catacccagg 660
 acagacacca ttaacatccc gaatcccatg tgcaactgca ttgccgcctt actgcactat 720
 tttctgtagg tgacatttac ctggaacgca ctcagcgtgc cacagctcta ttaccttcta 780
 ataaggacca tgaagcctct tcctcggcatt ttcattcttt tcatctcatt aattggatgg 840
 ggagtcctcag ctatagtagt ggctataaca gtgggagtta tttattctca gaatggaaat 900
 aatccacagt gggaattaga ctaccggcaa gagaaaatct gctggctggc aattccagaa 960
 cccaatggtg ttataaaaag tccgtgtttg tggtcattca tcgtacctgt aaccattatc 1020
 ctcatcagca atgttggtat gtttattaca atctcgatca aagtgtgtgt gaagaataac 1080
 cagaacctga caagcacaaa aaaagtttca tccatgaaga agattgtag cacattatct 1140
 gttgcagttg tttttggaat tacctggatt ctagcatacc tgatgctagt taatgatgat 1200
 agcatcagga tcgtcttcag ctacatattc tgccttttca acactacaca ggtatggtgc 1260
 ggattagtct ga 1272

<210> 10
 <211> 423
 <212> PRT
 <213> homo sapiens

<400> 10
 Met Pro Val Lys Met Leu Phe Lys Glu Leu Leu Leu Leu Met Met
 1 5 10 15
 Met Pro Leu Gln His Tyr Thr Lys Thr Cys Gly Phe Val Val Tyr Gln
 20 25 30
 Asn Asp Lys Leu Phe Gln Ser Lys Thr Phe Thr Ala Lys Ser Asp Phe
 35 40 45
 Ser Gln Lys Ile Ile Ser Ser Lys Thr Asp Glu Asn Glu Gln Asp Gln
 50 55 60
 Ser Ala Ser Val Asp Met Val Phe Ser Pro Lys Tyr Asn Gln Lys Glu
 65 70 75 80
 Phe Gln Leu Tyr Ser Tyr Ala Cys Val Tyr Trp Asn Leu Ser Ala Lys
 85 90 95
 Asp Trp Asp Thr Tyr Gly Cys Gln Lys Asp Lys Gly Thr Asp Gly Phe
 100 105 110
 Leu Arg Cys Arg Cys Asn His Thr Thr Asn Phe Ala Val Leu Met Thr
 115 120 125
 Phe Lys Lys Asp Tyr Gln Tyr Pro Lys Ser Leu Asp Ile Leu Ser Asn
 130 135 140
 Val Gly Cys Ala Leu Ser Val Thr Gly Leu Ala Leu Thr Val Ile Phe
 145 150 155 160
 Gln Ile Val Thr Arg Lys Val Arg Lys Thr Ser Val Thr Trp Val Leu
 165 170 175
 Val Asn Leu Cys Ile Ser Met Leu Ile Phe Asn Leu Leu Phe Val Phe
 180 185 190
 Gly Ile Glu Asn Ser Asn Lys Asn Leu Gln Thr Ser Asp Gly Asp Ile
 195 200 205
 Asn Asn Ile Asp Phe Asp Asn Asn Asp Ile Pro Arg Thr Asp Thr Ile

210	215	220
Asn Ile Pro Asn Pro Met Cys Thr Ala Ile Ala Leu Leu His Tyr		
225	230	235
Phe Leu Leu Val Thr Phe Thr Trp Asn Ala Leu Ser Ala Ala Gln Leu		
	245	250
Tyr Tyr Leu Leu Ile Arg Thr Met Lys Pro Leu Pro Arg His Phe Ile		
	260	265
Leu Phe Ile Ser Leu Ile Gly Trp Gly Val Pro Ala Ile Val Val Ala		
	275	280
Ile Thr Val Gly Val Ile Tyr Ser Gln Asn Gly Asn Asn Pro Gln Trp		
	290	295
Glu Leu Asp Tyr Arg Gln Glu Lys Ile Cys Trp Leu Ala Ile Pro Glu		
305	310	315
Pro Asn Gly Val Ile Lys Ser Pro Leu Leu Trp Ser Phe Ile Val Pro		
	325	330
Val Thr Ile Ile Leu Ile Ser Asn Val Val Met Phe Ile Thr Ile Ser		
	340	345
Ile Lys Val Leu Trp Lys Asn Asn Gln Asn Leu Thr Ser Thr Lys Lys		
	355	360
Val Ser Ser Met Lys Lys Ile Val Ser Thr Leu Ser Val Ala Val Val		
	370	375
Phe Gly Ile Thr Trp Ile Leu Ala Tyr Leu Met Leu Val Asn Asp Asp		
385	390	395
Ser Ile Arg Ile Val Phe Ser Tyr Ile Phe Cys Leu Phe Asn Thr Thr		
	405	410
Gln Val Trp Cys Gly Leu Val		
	420	

<210> 11

<211> 1683

<212> DNA

<213> homo sapiens

<400> 11

atggagactt	attccttgtc	tttgggtaat	caatcagtg	tggaacctaa	catagcaata	60
cagtcagcaa	atttctcttc	agaaaatgcg	gtggggcctt	caaagtgtcg	cttctctgtg	120
cagaaaggag	ctagcagttc	tctagtttct	agttcaacat	ttatacatat	aaatgtggat	180
ggccttaacc	cagatgcaca	gactgagctt	caggtcttgc	ttaatatgac	gaaaaattac	240
accaagacat	gcggctttgt	agtttatcaa	aatgacaagc	ttttccaatc	aaaaactttt	300
acagctaaat	cggatttttag	tcaaaaaatt	atctcaagca	aaactgatga	aaatgagcaa	360
gatcagagtg	cttctgttga	catggctctt	agtccaaagt	acaacccaaa	agaatttcaa	420
ctctattcct	atgcctgtgt	ctattggaat	ttgtcagcga	aggactggga	cacatatggc	480
tgtcaaaaag	acaagggcac	tgatggattc	ctgcgctgcc	gctgcaacca	tactactaat	540
tttgcgtgat	taatgacttt	caaaaaggat	tatcaatatc	ccaaatcact	tgacatatta	600
tccaacgttg	gatgtgcact	gtctgttact	ggctctggctc	tcacagttat	atttcagatt	660
gtcaccagga	aagtcagaaa	aacctcagta	acctgggttt	tggtcaatct	gtgcatatca	720
atgttgattt	tcaacctcct	ctttgtgttt	ggaattgaaa	actccaataa	gaacttgcag	780
acaagtgatg	gtgacatcaa	taatattgac	tttgacaata	atgacatacc	caggacagac	840
accattaaca	tcccgaatcc	catgtgcact	gogattgccg	ccttactgca	ctattttctg	900
ttagtgacat	ttacctggaa	cgactcagc	gotgcacagc	tctattacct	tctaataagg	960
accatgaagc	ctcttcctcg	gcatttcatt	cttttcatct	cattaattgg	atggggagtc	1020
ccagctatag	tagtggctat	aacagtggga	gttattttatt	ctcagaatgg	aaataatcca	1080
cagtgggaat	tagactaccg	gcaagagaaa	atctgctggc	tggcaattcc	agaacccaat	1140
ggtgttataa	aaagtccgct	gttgtggtca	ttcatcgtac	ctgtaaccat	tatcctcatc	1200
agcaatgttg	ttatgtttat	tacaatctcg	atcaaagtgc	tgtggaagaa	taaccagaac	1260
ctgacaagca	caaaaaaagt	ttcatccatg	aagaagattg	ttagcacatt	atctgttgca	1320
gttggttttg	gaattacctg	gattctagca	tacctgatgc	tagttaatga	tgatagcatc	1380
aggatcgtct	tcagctacat	attctgcctt	ttcaacacta	cacagggatt	gcaaattttt	1440
atcctgtaca	ctgttagaac	aaaagtcttc	cagagtgaag	cttccaaagt	gttgatgttg	1500
ctatcgtcta	ttgggagaag	gaagtcattg	ccttcagtga	cgcgcccgag	gctgcgtgta	1560
aagatgtata	atttcctcag	gtcattgcca	accttacctg	aacgctttag	gctactggaa	1620
acctctccga	gtactgagga	aatcacactc	tctgaaaagt	acaatgcaaa	ggaaagcatc	1680
tag						1683

<210> 12
 <211> 560
 <212> PRT
 <213> homo sapiens

<400> 12

Met	Glu	Thr	Tyr	Ser	Leu	Ser	Leu	Gly	Asn	Gln	Ser	Val	Val	Glu	Pro
1				5					10					15	
Asn	Ile	Ala	Ile	Gln	Ser	Ala	Asn	Phe	Ser	Ser	Glu	Asn	Ala	Val	Gly
			20					25					30		
Pro	Ser	Asn	Val	Arg	Phe	Ser	Val	Gln	Lys	Gly	Ala	Ser	Ser	Ser	Leu
		35					40					45			
Val	Ser	Ser	Ser	Thr	Phe	Ile	His	Thr	Asn	Val	Asp	Gly	Leu	Asn	Pro
	50					55					60				
Asp	Ala	Gln	Thr	Glu	Leu	Gln	Val	Leu	Leu	Asn	Met	Thr	Lys	Asn	Tyr
65					70					75					80
Thr	Lys	Thr	Cys	Gly	Phe	Val	Val	Tyr	Gln	Asn	Asp	Lys	Leu	Phe	Gln
			85					90						95	
Ser	Lys	Thr	Phe	Thr	Ala	Lys	Ser	Asp	Phe	Ser	Gln	Lys	Ile	Ile	Ser
			100					105					110		
Ser	Lys	Thr	Asp	Glu	Asn	Glu	Gln	Asp	Gln	Ser	Ala	Ser	Val	Asp	Met
		115					120					125			
Val	Phe	Ser	Pro	Lys	Tyr	Asn	Gln	Lys	Glu	Phe	Gln	Leu	Tyr	Ser	Tyr
	130					135					140				
Ala	Cys	Val	Tyr	Trp	Asn	Leu	Ser	Ala	Lys	Asp	Trp	Asp	Thr	Tyr	Gly
145					150					155					160
Cys	Gln	Lys	Asp	Lys	Gly	Thr	Asp	Gly	Phe	Leu	Arg	Cys	Arg	Cys	Asn
			165					170						175	
His	Thr	Thr	Asn	Phe	Ala	Val	Leu	Met	Thr	Phe	Lys	Lys	Asp	Tyr	Gln
			180					185					190		
Tyr	Pro	Lys	Ser	Leu	Asp	Ile	Leu	Ser	Asn	Val	Gly	Cys	Ala	Leu	Ser
		195				200						205			
Val	Thr	Gly	Leu	Ala	Leu	Thr	Val	Ile	Phe	Gln	Ile	Val	Thr	Arg	Lys
	210					215					220				
Val	Arg	Lys	Thr	Ser	Val	Thr	Trp	Val	Leu	Val	Asn	Leu	Cys	Ile	Ser
225					230					235					240
Met	Leu	Ile	Phe	Asn	Leu	Leu	Phe	Val	Phe	Gly	Ile	Glu	Asn	Ser	Asn
			245						250					255	
Lys	Asn	Leu	Gln	Thr	Ser	Asp	Gly	Asp	Ile	Asn	Asn	Ile	Asp	Phe	Asp
			260				265						270		
Asn	Asn	Asp	Ile	Pro	Arg	Thr	Asp	Thr	Ile	Asn	Ile	Pro	Asn	Pro	Met
		275				280						285			
Cys	Thr	Ala	Ile	Ala	Ala	Leu	Leu	His	Tyr	Phe	Leu	Leu	Val	Thr	Phe
	290					295					300				
Thr	Trp	Asn	Ala	Leu	Ser	Ala	Ala	Gln	Leu	Tyr	Tyr	Leu	Leu	Ile	Arg
305					310					315					320
Thr	Met	Lys	Pro	Leu	Pro	Arg	His	Phe	Ile	Leu	Phe	Ile	Ser	Leu	Ile
			325						330					335	
Gly	Trp	Gly	Val	Pro	Ala	Ile	Val	Val	Ala	Ile	Thr	Val	Gly	Val	Ile
			340					345					350		
Tyr	Ser	Gln	Asn	Gly	Asn	Asn	Pro	Gln	Trp	Glu	Leu	Asp	Tyr	Arg	Gln
		355					360					365			
Glu	Lys	Ile	Cys	Trp	Leu	Ala	Ile	Pro	Glu	Pro	Asn	Gly	Val	Ile	Lys
	370					375					380				
Ser	Pro	Leu	Leu	Trp	Ser	Phe	Ile	Val	Pro	Val	Thr	Ile	Ile	Leu	Ile
385					390					395					400
Ser	Asn	Val	Val	Met	Phe	Ile	Thr	Ile	Ser	Ile	Lys	Val	Leu	Trp	Lys
			405						410					415	
Asn	Asn	Gln	Asn	Leu	Thr	Ser	Thr	Lys	Lys	Val	Ser	Ser	Met	Lys	Lys
			420					425					430		
Ile	Val	Ser	Thr	Leu	Ser	Val	Ala	Val	Val	Phe	Gly	Ile	Thr	Trp	Ile
		435					440					445			


```

Leu Ala Tyr Leu Met Leu Val Asn Asp Asp Ser Ile Arg Ile Val Phe
  450          455          460
Ser Tyr Ile Phe Cys Leu Phe Asn Thr Thr Gln Gly Leu Gln Ile Phe
  465          470          475          480
Ile Leu Tyr Thr Val Arg Thr Lys Val Phe Gln Ser Glu Ala Ser Lys
          485          490          495
Val Leu Met Leu Leu Ser Ser Ile Gly Arg Arg Lys Ser Leu Pro Ser
          500          505          510
Val Thr Arg Pro Arg Leu Arg Val Lys Met Tyr Asn Phe Leu Arg Ser
          515          520          525
Leu Pro Thr Leu His Glu Arg Phe Arg Leu Leu Glu Thr Ser Pro Ser
          530          535          540
Thr Glu Glu Ile Thr Leu Ser Glu Ser Asp Asn Ala Lys Glu Ser Ile
  545          550          555          560

```

<210> 13
 <211> 1509
 <212> DNA
 <213> homo sapiens

```

<400> 13
atgccagtgagatgcttttcaaagagttgctgctactgctaatagatgatgcccttacaa60
cattacaccaagacatgcggtttgttagtttatcaaaatgacaagcttttccaatcaaaa120
acttttacagctaaatcgga ttttagtcaa aaaattatctcaagcaaaactgatgaaaat180
gagcaagatcagagtgccttcgtttgacatggtcttttagtc caaagtacaa ccaaaaagaa240
tttcaactctattcctatgctgtgtctattggaatttgcagcgaagga ctgggacaca300
tatggctgtc aaaaagacaa gggcactgat ggattcctgc gctgccgctg caaccatact360
actaattttgctgtattaatgactttcaaa aaggattatcaatatcccaa atcacttgac420
atattatccaacgttggatgtgactgtctgttactggctcaggctctcac agttatattt480
cagattgtcaccaggaaagt cagaaaaacc tcagtaacctgggttttgggccaatctgtgc540
atatcaatgttgattttcaacctcctctttgtgtttggaa ttgaaaactccaataagaac600
ttgcagacaa gtgatgggtgacatcaataat attgactttgacaataatgacataccagg660
acagacacca ttaacatccc gaatcccatg tgcactgcga ttgccgcctt actgcactat720
tttctgttagtgacatttacctggaacgcacacagctctacacagctcta ttaccttcta780
ataaggacca tgaagcctcttctcggcat ttcattcttttcactctcatt aattggatgg840
ggagtccagctatagtagtggctataacagtgggagttattattctcagaatggaaat900
aatccacagtggaattagactaccggcaagagaaaatctgctggctggcaattccagaa960
cccaatgggtgtataaaaagtccgctgttg tggtcattcatcgtacctgt aaccattatc1020
ctcatcagcaatgttattgtttattaca atctcgatca aagtgcgttggaagaataac1080
cagaacctgacaagcaca aaaagttttccatgaaga agattgttagcacattatct1140
gttgcagttgtttttggaattacctggattctagcatacc tgatgctagttaatgatgat1200
agcatcagga tgcgtcttcagctacatattc tgccttttcaacactacacagggtattgcaa1260
atttttatcc tgtacactgt tagaacaaaa gtcttccagagtgaagcttc caaagtgttg1320
atgttgctatcgtctattgg gagaagggaagtcattgccttcagtgcgcggccgaggctg1380
cgtgtaaagatgtataatttcctcaggtcattgccaaccttacatgaacgctttaggcta1440
ctggaaacctctccgagtactgaggaaatcacactctctgaaagtgacaa tgcaaaggaa1500
agcatctag

```

<210> 14
 <211> 502
 <212> PRT
 <213> homo sapiens

```

<400> 14
Met Pro Val Lys Met Leu Phe Lys Glu Leu Leu Leu Leu Met Met
  1          5          10          15
Met Pro Leu Gln His Tyr Thr Lys Thr Cys Gly Phe Val Val Tyr Gln
          20          25          30
Asn Asp Lys Leu Phe Gln Ser Lys Thr Phe Thr Ala Lys Ser Asp Phe
          35          40          45
Ser Gln Lys Ile Ile Ser Ser Lys Thr Asp Glu Asn Glu Gln Asp Gln
          50          55          60
Ser Ala Ser Val Asp Met Val Phe Ser Pro Lys Tyr Asn Gln Lys Glu

```

65					70					75				80
Phe	Gln	Leu	Tyr	Ser	Tyr	Ala	Cys	Val	Tyr	Trp	Asn	Leu	Ser	Ala
				85					90					95
Asp	Trp	Asp	Thr	Tyr	Gly	Cys	Gln	Lys	Asp	Lys	Gly	Thr	Asp	Gly
			100					105					110	
Leu	Arg	Cys	Arg	Cys	Asn	His	Thr	Thr	Asn	Phe	Ala	Val	Leu	Met
		115					120					125		
Phe	Lys	Lys	Asp	Tyr	Gln	Tyr	Pro	Lys	Ser	Leu	Asp	Ile	Leu	Ser
	130					135					140			
Val	Gly	Cys	Ala	Leu	Ser	Val	Thr	Gly	Leu	Ala	Leu	Thr	Val	Ile
	145				150					155				160
Gln	Ile	Val	Thr	Arg	Lys	Val	Arg	Lys	Thr	Ser	Val	Thr	Trp	Val
			165					170						175
Val	Asn	Leu	Cys	Ile	Ser	Met	Leu	Ile	Phe	Asn	Leu	Leu	Phe	Val
			180					185					190	
Gly	Ile	Glu	Asn	Ser	Asn	Lys	Asn	Leu	Gln	Thr	Ser	Asp	Gly	Asp
		195				200						205		
Asn	Asn	Ile	Asp	Phe	Asp	Asn	Asn	Asp	Ile	Pro	Arg	Thr	Asp	Thr
	210					215					220			
Asn	Ile	Pro	Asn	Pro	Met	Cys	Thr	Ala	Ile	Ala	Ala	Leu	Leu	His
	225				230					235				Tyr
Phe	Leu	Leu	Val	Thr	Phe	Thr	Trp	Asn	Ala	Leu	Ser	Ala	Ala	Gln
			245					250						255
Tyr	Tyr	Leu	Leu	Ile	Arg	Thr	Met	Lys	Pro	Leu	Pro	Arg	His	Phe
		260					265						270	
Leu	Phe	Ile	Ser	Leu	Ile	Gly	Trp	Gly	Val	Pro	Ala	Ile	Val	Val
	275					280						285		
Ile	Thr	Val	Gly	Val	Ile	Tyr	Ser	Gln	Asn	Gly	Asn	Asn	Pro	Gln
	290					295					300			
Glu	Leu	Asp	Tyr	Arg	Gln	Glu	Lys	Ile	Cys	Trp	Leu	Ala	Ile	Pro
	305				310					315				320
Pro	Asn	Gly	Val	Ile	Lys	Ser	Pro	Leu	Leu	Trp	Ser	Phe	Ile	Val
			325					330						335
Val	Thr	Ile	Ile	Leu	Ile	Ser	Asn	Val	Val	Met	Phe	Ile	Thr	Ile
		340					345					350		
Ile	Lys	Val	Leu	Trp	Lys	Asn	Asn	Gln	Asn	Leu	Thr	Ser	Thr	Lys
	355					360						365		
Val	Ser	Ser	Met	Lys	Lys	Ile	Val	Ser	Thr	Leu	Ser	Val	Ala	Val
	370					375					380			
Phe	Gly	Ile	Thr	Trp	Ile	Leu	Ala	Tyr	Leu	Met	Leu	Val	Asn	Asp
	385				390				395					400
Ser	Ile	Arg	Ile	Val	Phe	Ser	Tyr	Ile	Phe	Cys	Leu	Phe	Asn	Thr
			405					410					415	
Gln	Gly	Leu	Gln	Ile	Phe	Ile	Leu	Tyr	Thr	Val	Arg	Thr	Lys	Val
		420						425					430	
Gln	Ser	Glu	Ala	Ser	Lys	Val	Leu	Met	Leu	Leu	Ser	Ser	Ile	Gly
		435					440				445			
Arg	Lys	Ser	Leu	Pro	Ser	Val	Thr	Arg	Pro	Arg	Leu	Arg	Val	Lys
	450					455					460			
Tyr	Asn	Phe	Leu	Arg	Ser	Leu	Pro	Thr	Leu	His	Glu	Arg	Phe	Arg
	465				470				475					480
Leu	Glu	Thr	Ser	Pro	Ser	Thr	Glu	Glu	Ile	Thr	Leu	Ser	Glu	Ser
			485					490					495	
Asn	Ala	Lys	Glu	Ser	Ile									
			500											

<210> 15

<211> 726

<212> DNA

<213> homo sapiens

<400> 15

atgttgattt tcaacctcct ctttgtgttt ggaattgaaa actccaataa gaacttgacg

60

```

acaagtgatg gtgacatcaa taatattgac tttgacaata atgacatacc caggacagac 120
accattaaca tcccgaatcc catgtgcact gcgattgccg ccttactgca ctattttctg 180
ttagtgacat ttacctggaa cgcactcagc gctgcacagc tctattacct tctaataagg 240
accatgaagc ctcttcctcg gcatttcatt cttttcatct cattaattgg atggggagtc 300
ccagctatag tagtggctat aacagtggga gttattttatt ctcagaatgg aaataatcca 360
cagtgggaat tagactaccg gcaagagaaa atctgctggc tggcaattcc agaaccaat 420
ggtgttataa aaagtccgct gttgtgggtca ttcacgtac ctgtaaccat tatcctcatc 480
agcaatgttg ttatgtttat tacaatctcg atcaaagtgc tgtggaagaa taaccagaac 540
ctgacaagca caaaaaaagt ttcattccatg aagaagattg ttagcacatt atctgttgca 600
gttggttttg gaattacctg gattctagca tacctgatgc tagttaatga tgatagcatc 660
aggatcgctc tcagctacat attctgcctt ttcaacacta cacaggatg gtgcggatta 720
gtctga 726

```

<210> 16

<211> 241

<212> .PRT

<213> homo sapiens

<400> 16

```

Met Leu Ile Phe Asn Leu Leu Phe Val Phe Gly Ile Glu Asn Ser Asn
1      5      10      15
Lys Asn Leu Gln Thr Ser Asp Gly Asp Ile Asn Asn Ile Asp Phe Asp
20     25     30
Asn Asn Asp Ile Pro Arg Thr Asp Thr Ile Asn Ile Pro Asn Pro Met
35     40     45
Cys Thr Ala Ile Ala Ala Leu Leu His Tyr Phe Leu Leu Val Thr Phe
50     55     60
Thr Trp Asn Ala Leu Ser Ala Ala Gln Leu Tyr Tyr Leu Leu Ile Arg
65     70     75     80
Thr Met Lys Pro Leu Pro Arg His Phe Ile Leu Phe Ile Ser Leu Ile
85     90     95
Gly Trp Gly Val Pro Ala Ile Val Val Ala Ile Thr Val Gly Val Ile
100    105    110
Tyr Ser Gln Asn Gly Asn Asn Pro Gln Trp Glu Leu Asp Tyr Arg Gln
115    120    125
Glu Lys Ile Cys Trp Leu Ala Ile Pro Glu Pro Asn Gly Val Ile Lys
130    135    140
Ser Pro Leu Leu Trp Ser Phe Ile Val Pro Val Thr Ile Ile Leu Ile
145    150    155    160
Ser Asn Val Val Met Phe Ile Thr Ile Ser Ile Lys Val Leu Trp Lys
165    170    175
Asn Asn Gln Asn Leu Thr Ser Thr Lys Lys Val Ser Ser Met Lys Lys
180    185    190
Ile Val Ser Thr Leu Ser Val Ala Val Val Phe Gly Ile Thr Trp Ile
195    200    205
Leu Ala Tyr Leu Met Leu Val Asn Asp Asp Ser Ile Arg Ile Val Phe
210    215    220
Ser Tyr Ile Phe Cys Leu Phe Asn Thr Thr Gln Val Trp Cys Gly Leu
225    230    235    240
Val

```

<210> 17

<211> 963

<212> DNA

<213> homo sapiens

<400> 17

```

atgttgattt tcaacctcct ctttgtgttt ggaattgaaa actccaataa gaacttgcag 60
acaagtgatg gtgacatcaa taatattgac tttgacaata atgacatacc caggacagac 120
accattaaca tcccgaatcc catgtgcact gcgattgccg ccttactgca ctattttctg 180
ttagtgacat ttacctggaa cgcactcagc gctgcacagc tctattacct tctaataagg 240
accatgaagc ctcttcctcg gcatttcatt cttttcatct cattaattgg atggggagtc 300

```

```

ccagctatag tagtggctat aacagtggga gttattttatt ctcagaatgg aaataatcca 360
cagtgggaat tagactaccg gcaagagaaa atctgctggc tggcaattcc agaaccaat 420
ggtgttataa aaagtcgct gttgtgggtca ttcacgtac ctgtaaccat taccctcatc 480
agcaatgttg ttatgtttat tacaatctcg atcaaagtgc tgtggaagaa taaccagaac 540
ctgacaagca caaaaaaagt ttcattccatg aagaagattg ttagcacatt atctgttgca 600
gttgtttttg gaattacctg gattctagca tacctgatgc tagttaatga tgatagcatc 660
aggatcgtct tcagctacat attctgcctt ttcaacacta cacagggatt gcaaattttt 720
atcctgtaca ctgttagaac aaaagtcttc cagagtgaag cttccaaagt gttgatgttg 780
ctatcgtcta ttgggagaag gaagtcattg ccttcagtga cgcggccgag gctgcgtgta 840
aagatgtata atttctcag gtcattgcca accttacatg aacgctttag gctactggaa 900
acctctccga gtactgagga aatcacactc tctgaaagtg acaatgcaaa ggaaagcatc 960
tag 963

```

<210> 18

<211> 320

<212> PRT

<213> homo sapiens

<400> 18

```

Met Leu Ile Phe Asn Leu Leu Phe Val Phe Gly Ile Glu Asn Ser Asn
1      5      10
Lys Asn Leu Gln Thr Ser Asp Gly Asp Ile Asn Asn Ile Asp Phe Asp
20     25     30
Asn Asn Asp Ile Pro Arg Thr Asp Thr Ile Asn Ile Pro Asn Pro Met
35     40     45
Cys Thr Ala Ile Ala Ala Leu Leu His Tyr Phe Leu Leu Val Thr Phe
50     55     60
Thr Trp Asn Ala Leu Ser Ala Ala Gln Leu Tyr Tyr Leu Leu Ile Arg
65     70     75     80
Thr Met Lys Pro Leu Pro Arg His Phe Ile Leu Phe Ile Ser Leu Ile
85     90     95
Gly Trp Gly Val Pro Ala Ile Val Val Ala Ile Thr Val Gly Val Ile
100    105    110
Tyr Ser Gln Asn Gly Asn Asn Pro Gln Trp Glu Leu Asp Tyr Arg Gln
115    120    125
Glu Lys Ile Cys Trp Leu Ala Ile Pro Glu Pro Asn Gly Val Ile Lys
130    135    140
Ser Pro Leu Leu Trp Ser Phe Ile Val Pro Val Thr Ile Ile Leu Ile
145    150    155    160
Ser Asn Val Val Met Phe Ile Thr Ile Ser Ile Lys Val Leu Trp Lys
165    170    175
Asn Asn Gln Asn Leu Thr Ser Thr Lys Lys Val Ser Ser Met Lys Lys
180    185    190
Ile Val Ser Thr Leu Ser Val Ala Val Val Phe Gly Ile Thr Trp Ile
195    200    205
Leu Ala Tyr Leu Met Leu Val Asn Asp Asp Ser Ile Arg Ile Val Phe
210    215    220
Ser Tyr Ile Phe Cys Leu Phe Asn Thr Thr Gln Gly Leu Gln Ile Phe
225    230    235    240
Ile Leu Tyr Thr Val Arg Thr Lys Val Phe Gln Ser Glu Ala Ser Lys
245    250    255
Val Leu Met Leu Leu Ser Ser Ile Gly Arg Arg Lys Ser Leu Pro Ser
260    265    270
Val Thr Arg Pro Arg Leu Arg Val Lys Met Tyr Asn Phe Leu Arg Ser
275    280    285
Leu Pro Thr Leu His Glu Arg Phe Arg Leu Leu Glu Thr Ser Pro Ser
290    295    300
Thr Glu Glu Ile Thr Leu Ser Glu Ser Asp Asn Ala Lys Glu Ser Ile
305    310    315    320

```

<210> 19

<211> 3057

<212> DNA

<213> homo sapiens

<400> 19

ggcggcgccg	gcgccctccg	caagccgtct	ttctctagag	ttgtatatat	agaacatcct	60
ggagtccacc	atgaacggac	agttggatct	aagtgggaag	ctaatacatca	aagctcaact	120
tggggaggat	attcggcgaa	ttcctattca	taatgaagat	attacttatg	atgaattagt	180
gctaattgatg	caacgagttt	tcagaggaaa	acttctgagt	aatgatgaag	taacaataaa	240
gtataaagat	gaagatggag	atccttataac	aatttttgat	agttctgacc	tttcctttgc	300
aattcagtg	agtaggatac	tgaaactgac	attatttgga	aaatctactt	cctcatcaag	360
cacccctaca	gagttctgca	ggaatggtgg	aacctgggaa	aatggcagat	gtattttgtac	420
agaagagtgg	aaaggactga	gatgtacaat	tgctaatttt	tgtgaaaata	gtacctatat	480
gggttttact	tttgccagaa	tcccagtg	cagatatgga	ccatccttgc	aaacatgtgg	540
caaggatact	ccaaatgcgg	gcaatccaat	ggcagtcg	ttgtgcagtc	tctctctata	600
tggagagata	gaattacaaa	aagtgacaa	aggaaattgc	aatgaaaatc	tggaaacctc	660
ggaaaagcag	gtaaaggatg	tcacagcacc	acttaataac	atttctctg	aagtcagat	720
tttaacatct	gatgccaaata	aattaactgc	tgagaacatc	actagtgc	cgcgagtggt	780
tggacagata	ttcaacactt	ccagaaatgc	ttcacctgag	gcaaagaaag	ttgccatagt	840
aacagtga	caactcctag	atgccagtg	agatgctttt	caaagagttg	ctgctactgc	900
taatgatgat	gcctttacaa	cgcttattga	gcaaatggag	acttattcct	tgtctttggg	960
taatcaatca	gtggtggaac	ctaacatagc	aatacagtc	gcaaattttct	cttcagaaaa	1020
tgcggtggg	ccttcaaatg	ttcgcttctc	tgtgcagaaa	ggagctagca	gttctctagt	1080
ttctagtcca	acatttatac	atacaaatgt	ggatggcctt	aaccagatg	cacagatg	1140
gcttcaggtc	ttgcttaata	tgacgaaaaa	ttacaccaag	acatgcggt	ttgtagtcca	1200
tcaaatgac	aagcttttcc	aatcaaaaac	ttttacagct	aaatcggatt	ttagtcaaaa	1260
aattatctca	agcaaaactg	atgaaaatga	gcaagatcag	agtgttctg	ttgacatggt	1320
ctttagtcca	aagtacaacc	aaaaagaatt	tcaactctat	tccatgcct	gtgtctattg	1380
gaatttgtca	gcgaaggact	gggacacata	tggctgtcaa	aaagacaagg	gcactgatgg	1440
attcctgcg	tgcgctgca	accatactac	taattttgct	gtattaatga	ctttcaaaaa	1500
ggattatcaa	tatcccaaat	cacttgacat	attatccaac	gttggtatg	cactgtctgt	1560
tactggtctg	gctctcacag	ttatatttca	gattgtcacc	aggaaagtca	gaaaaacctc	1620
agtaacctgg	gttttggtca	atctgtgcat	atcaatgttg	attttcaacc	tccctcttgt	1680
gtttggaatt	gaaaactcca	ataagaactt	gcagacaagt	gatggtgaca	tcaataatat	1740
tgactttgac	aataatgaca	taccaggac	agacaccatt	aacatcccga	atcccagtgt	1800
cactgcgatt	gccgccttac	tgcactattt	tctgttagtg	acatttacct	ggaacgcact	1860
cagcgtgca	cagctctatt	accttcta	aaggaccatg	aagcctcttc	ctcggcattt	1920
cattcttttc	atctcattaa	ttggatgggg	agtcacagct	atagttagtg	ctataacagt	1980
gggagttatt	tattctcaga	atggaaataa	tccacagtgg	gaattagact	accggcaaga	2040
gaaaatctgc	tggctggcaa	ttccagaacc	caatggtgtt	ataaaaagtc	cgctgttgtg	2100
gtcattcatc	gtacctgtaa	ccattatcct	catcagcaat	gttggtatgt	ttattacaat	2160
ctcgatcaaa	gtgctgtgga	agaataacca	gaacctgaca	agcacaataa	aagtttcac	2220
catgaagaag	attgttagca	cattatctgt	tgcaagttgt	tttggaatta	cctggattct	2280
agcatacctg	atgctagtta	atgatgatag	catcaggatc	gtcttcagct	acatattctg	2340
ccttttcaac	actacacagg	gattgcaaat	ttttatcctg	tacactgtta	gaacaaaagt	2400
cttccagagt	gaagcttcca	aagtgttgat	gttgctatcg	tctattggga	gaaggaaagtc	2460
attgccttca	gtgacgcggc	cgaggctgcg	tgtaaagatg	tataatttcc	tcaggtcatt	2520
gccaacctta	catgaacgct	ttaggtact	ggaacctct	ccgagtactg	aggaaatcac	2580
actctctgaa	agtgacaatg	caaaggaaa	catctagaca	gtaaaactta	cctgtgtgtg	2640
tctttttaat	caoctcgttt	gagttttatc	tgtttctctc	ctttatttcc	cagtcctctc	2700
agaaagtctt	cctcaatgta	ttttgtcag	gattaagaat	tagataaaac	ctgttgttta	2760
ttattattcg	gcataatgga	cttggtagt	tttctatttt	tcaatagatt	tgtacttgaa	2820
taaggtgaag	aatttcacac	aacatacaag	agtaaccattg	ttccttatat	cgttaaatct	2880
ttgtgacaca	ctttgacaaa	aatgtagaac	ctataacaaa	ttcttttaca	agttactata	2940
aaggacacaa	agagaaaact	ttaccttcca	gaacaaaatg	actcctgatg	aacagtgtgt	3000
ggggatttgc	ttgtatgtat	taaacttttg	acctctgaaa	aaaaaaaaaa	aaaaaaa	3057